<allTrials totalCount="61" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2007-12-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-12-21T00:00:00.000Z">23612807</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentre randomised placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease</title>
      <scientificTitle/>
      <acronym>CANOX trial</acronym>
      <studyHypothesis>Long-term oxygen therapy (LTOT) is the only component of the management of chronic obstructive pulmonary disease (COPD) that improves survival in patients with severe daytime hypoxemia. In Canada, LTOT is usually provided by a stationary oxygen concentrator and is recommended to be used for at least 15 - 18 hours a day. Several studies have demonstrated a deterioration in arterial blood gas pressures and oxygen saturation during sleep in patients with COPD. Sleep-related oxygen desaturation often occurs in patients not qualifying for LTOT. The suggestion has been made that the natural progression of COPD to its end stages of chronic pulmonary hypertension, severe hypoxemia, right heart failure, and death is dependent upon the severity of desaturation occurring during sleep. This is an attractive hypothesis and is supported by the fact that hypoxemic episodes during sleep are accompanied by substantial increases in pulmonary arterial pressure and often by important cardiac arrhythmias. Supplemental nocturnal oxygen alleviates both the acute increases in pulmonary arterial pressure and the cardiac arrhythmias.  

It has been suggested that, over the long run, nocturnal oxygen therapy (N-O2) may halt the progression of long-standing cor pulmonale and prolong survival. Probably due to the fact that the recommendations of scientific societies regarding the indications for and use of N-O2 in COPD not qualifying for conventional LTOT are presently imprecise, a number of patients are currently treated with N-O2 although the beneficial effects of this therapy have not been confirmed.

Hypothesis:
In patients with Chronic Obstructive Pulmonary Disease (COPD) not qualifying for Long Term Oxygen Therapy (LTOT) but who present significant nocturnal arterial oxygen desaturation, nocturnal oxygen therapy provided for a period of 3 years is effective in decreasing mortality or delaying the requirement for LTOT, and is cost-effective and favourably compares to other medical interventions</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcomes of this trial are mortality from all cause or requirement for LTOT (composite outcome).</primaryOutcome>
      <secondaryOutcome>1. Quality of life and utility measures
2. Costs from a societal perspective 
3. Compliance with oxygen therapy</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Pending as of 20/10/2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23612807</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MOP-36329</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A 3-year, multicentre, placebo-controlled, randomised trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2013-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="883624d6-4d6d-4c28-9130-caa5da73b5cf">
	  <name>Centre de Pneumologie</name>
	  <address/>
	  <city>Québec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>G1V 4G5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with a diagnosis of COPD supported by an history of past or current smoking and obstructive disease with forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) less than 60%
2. Presence of mild-to-moderate daytime hypoxemia with a daytime partial pressure of oxygen in arterial blood (paO2) in the range of 56 - 69 mmHg
3. Patients fulfilling our definition of nocturnal oxygen desaturation: greater than or equal to 30% of the recording time with transcutaneous arterial oxygen saturation less than 90% on two consecutive recordings</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>1. Patients fulfilling the usual criteria for continuous oxygen therapy (CONT-O2) at study entry: 
1.1. PaO2 less than or equal to 55 mmHg, or
1.2. PaO2 less than or equal to 59 mmHg with clinical evidence of at least one of the following: 
1.2.1. Pulmonary hypertension
1.2.2. Right ventricular hypertrophy
1.2.3. Cor pulmonale
1.2.4. Haematocrit greater than or equal to 55%
2. Patients with sleep apnea (defined by an apnoea/hypopnoea index of greater than or equal to 15 events/hour
3. Patients currently on nocturnal oxygen therapy (N-O2)
4. Patients with known left heart or congenital heart diseases, interstitial lung diseases, bronchiectasis as the main cause of their obstructive disease, lung carcinoma or other severe diseases that could influence survival (hepatic cirrhosis and chronic renal failure)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2013-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic obstructive pulmonary disease (COPD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Nocturnal oxygen therapy group: N-O2 will be delivered overnight to allow the oxygen saturation to be greater than 90%
2. Placebo: the patients allocated in the control group will receive room air delivered by sham concentrator</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nocturnal oxygen therapy</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15743-0</funderId>
      <contactId>Contact53681_15743</contactId>
      <sponsorId>Sponsor52235</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53681_15743">
    <title>Dr</title>
    <forename>Yves</forename>
    <surname>Lacasse</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre de Pneumologie
Hôpital Laval
2725 chemin Ste-Foy</address>
      <city>Québec</city>
      <country>Canada</country>
      <zip>G1V 4G5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 418 656 4747</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yves.lacasse@med.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52235">
    <organisation>Laval University (Canada)</organisation>
    <website>http://www.ulaval.ca/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Cité Universitaire
C.P. 2208</address>
      <city>Québec</city>
      <country>Canada</country>
      <zip>G1K 7P4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yves.lacasse@med.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.23856.3a</gridId>
    <rorId>https://ror.org/04sjchr03</rorId>
  </sponsor>
  <funder id="Funder15743-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MOP-36329)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-12-18T00:00:00.000Z">34931928</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of homocysteine-lowering vitamin supplementation on migraine disability</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does vitamin therapy including folic acid reduce homocysteine and migraine disability, and is the effect dependent on MTHFR genotype?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Migraine disability, as measured using the Migraine Disability Assessment (MIDAS) score at baseline and 6 months.</primaryOutcome>
      <secondaryOutcome>1. Migraine frequency. Duration of follow-up: 6 months
2. Migraine pain: MIDAS pain score 1-10 (10 = most severe) at baseline and 6 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Griffith University Ethics Committee on 11 November 2005 (ref: 3425)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34931928</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="11a24be8-9a86-4feb-b250-fa2667ed342a">
	  <name>Griffith University</name>
	  <address/>
	  <city>Gold Coast</city>
	  <state/>
	  <country>Australia</country>
	  <zip>9726</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Current diagnosis of regular migraine with aura attacks
2. &gt;18 and &lt;70 years old</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Co-morbid vascular or neuropsychiatric disease
2. Pregnant
3. Currently taking B vitamins</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Migraine with aura</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Migraine with aura</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Daily B vitamin (B6, B9, B12) therapy vs placebo for 6 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17311-0</funderId>
      <contactId>Contact55272_17311</contactId>
      <sponsorId>Sponsor53840</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55272_17311">
    <title>Prof</title>
    <forename>Lyn</forename>
    <surname>Griffiths</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Griffith University
Gold Coast campus</address>
      <city>Gold Coast</city>
      <country>Australia</country>
      <zip>9726</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">L.Griffiths@griffith.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53840">
    <organisation>Griffith University (Australia)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof Lyn Griffiths
Gold Coast campus
Griffith University Qld 4222</address>
      <city>Gold Coast</city>
      <country>Australia</country>
      <zip>9726</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">L.Griffiths@griffith.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.1022.1</gridId>
    <rorId>https://ror.org/02sc3r913</rorId>
  </sponsor>
  <funder id="Funder17311-0">
    <name>Brain Foundation of Australia</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-12-18T00:00:00.000Z">35143689</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Candesartan in renal artery stenosis (CARLAS)</title>
      <scientificTitle/>
      <acronym>CARLAS</acronym>
      <studyHypothesis>Despite beneficial effects on blood pressure with endovascular treatment, the prognosis remains ominous in patients with renal artery stenosis because of increased cardiovascular mortality. In patients with atherosclerotic renal artery stenosis, the mortality is increased six-fold compared to an age-matched population. It is reasonable to speculate that the high cardiovascular mortality in patients with renal artery stenosis could partly be explained by increased inflammatory activity caused by activation of the renin-angiotensin system. We believe that Percutaneous Transluminal Renal Angioplasty (PTRA) followed by angiotensin receptor blockade may improve this disease state. 

The angiotensin receptor blocker candesartan given to patients with renovascular hypertension post-PTRA, will improve long-term renal function  (3 years) and decrease the risk of restenosis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Renal function measured by EDTA-clearance and frequency of restenosis 3 years after PTRA.</primaryOutcome>
      <secondaryOutcome>Cardiovascular events 3 years after PTRA.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethical Committees of the Universities of Göteborg and Lund on the 14th of April 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35143689</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>S 131-03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A two-center randomized controlled open study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-04-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d7bae0d5-a852-4018-85f3-2d76806b2d80">
	  <name>Department of Nephrology</name>
	  <address/>
	  <city>Göteborg</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>413 45</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Blood pressure above 140 mmHg/90 mmHg
2. Confirmation of renal artery stenosis by either duplex ultrasonography, CT-angiography or MR-angiography</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Renal size &lt;7.5 cm at the stenotic side 
2. Age &gt;80 years 
3. Pregnancy or nursing mother 
4. Terminal renal failure (Glomerular Filtration Rate [GFR] &lt;15 ml/min) 
5. Treatment with Angiotensin-Converting Enzyme (ACE) inhibitors or angiotensin receptor blockers 
6. Renovascular hypertension of other etiology than atherosclerosis or Flow-Mediated Dilation (FMD) 
7. Chronic glomerular disease with urinary albumin excretion (in mg/24h) (tU-alb) &gt;1g/day 
8. Diabetic nephropathy with tU-alb &gt;0.3 g/day 
9. Contraindication for renal angiography/PTRA (eg. serious contrast allergy)
10. Other forms of secondary hypertension 
11. Serious malignant disease 
12. Treatment with immune-modulating medications eg. cyclosporin and oral steroids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-04-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Renal artery stenosis</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Renal artery stenosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This study is carried out at two centers in Sweden (Göteborg and Malmö). 

Four weeks after renal angioplasty, all subjects will be randomized to anti-hypertensive treatment with either candesartan (oral) (intervention group) or conventional anti-hypertensive treatment (control group). The choice of drug used for the treatment of each participant in the control group will depend on his/her condition. The choices are betablockers, calcium antagonists, diuretics and alphablockers. 

The maximum daily doses: 200 mg for metoprolol (betablocker), 20 mg for felodipine (calcium antagonist), as much as needed for furosemide (diuretic), 8 mg for doxazosin (alphablocker). Candesartan was titrated up to a dose of 16 mg once daily.

Duration of intervention: three years</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Candesartan</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17182-0</funderId>
      <funderId>Funder17182-1</funderId>
      <funderId>Funder17182-2</funderId>
      <funderId>Funder17182-3</funderId>
      <funderId>Funder17182-4</funderId>
      <funderId>Funder17182-5</funderId>
      <funderId>Funder17182-6</funderId>
      <funderId>Funder17182-7</funderId>
      <funderId>Funder17182-8</funderId>
      <contactId>Contact55143_17182</contactId>
      <sponsorId>Sponsor53708</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55143_17182">
    <title>Prof</title>
    <forename>Hans</forename>
    <surname>Herlitz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Nephrology
Sahlgrenska University Hospital</address>
      <city>Göteborg</city>
      <country>Sweden</country>
      <zip>413 45</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 31 3428477</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hans.herlitz@medic.gu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53708">
    <organisation>AstraZeneca (Sweden)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Argongatan 2D</address>
      <city>Mölndal</city>
      <country>Sweden</country>
      <zip>431 86</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 31 7788500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mikael.forsby@astrazeneca.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.418151.8</gridId>
    <rorId>https://ror.org/04wwrrg31</rorId>
  </sponsor>
  <funder id="Funder17182-0">
    <name>The Ernhold Lundström Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-1">
    <name>Research Funds at Malm General (University) Hospital (Malm Allmnna Sjukhus - MAS) (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-2">
    <name>The Albert Påhlsson Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-3">
    <name>The Hulda Ahlmroth Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-4">
    <name>The Göteborg Medical Society (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-5">
    <name>The Swedish Medical Society</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-6">
    <name>The Swedish Association for Kidney Patients</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-7">
    <name>AstraZeneca, Mölndal (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-8">
    <name>The Swedish state under the LUA/ALF agreement</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-12-18T00:00:00.000Z">08808171</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness of the follow-up of depressed patients by  nurses</title>
      <scientificTitle/>
      <acronym>MADEIRA</acronym>
      <studyHypothesis>1. The average depressive symptoms at the end of six months of follow-up among the group of depression patients treated by the primary care nurse and the group treated by the family doctor do not exceed the difference of 2.5 on the BDI scale, which is considered a difference not clinically relevant. 
2. There will be no significant difference in change in the quality of life between the two groups. 
3. Level of satisfaction will be similar in both groups, or greater among patients followed by nurses than the participants who are treated by the doctors
4. Adherence to treatment will be similar in both groups, or higher in patients followed by the nurses</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Differences between groups in the average of decrease in depression symptoms, measured by BDI at 6 months
2. Increase in quality of life, measured by the 12-item Short Form health survey (SF-12) at 6 months
3. Increase in satisfaction with the professional, measured by the satisfaction questionnaire of Baker at 6 months</primaryOutcome>
      <secondaryOutcome>1. Percentage of acceptance of the intervention (comparison of the two groups): patient satisfaction and losses that occur at different times of follow-up
2. Average of differences between the two groups with respect to:
2.1. Frequency and duration of visits
2.2. Referrals
2.3. Drug treatment
3. Comparison of adherence to treatment between the two groups</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Research Ethics Committee of the Jordi Gol i Gurina Primary Care Research Institute (IDIAP), Barcelona, on 4 July 2006 (ref: P06/39)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08808171</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PI061281</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b3dc29f4-7c76-4de9-9699-4a82e7579c5d">
	  <name>Lope de Vega 138</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08005</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients between 25 and 70 years of age
2. Rating of 20 or more points in the Beck Depression Inventory Scale (BDI) 
3. Whose family practitioner thinks they suffer from depression and they need to initiate anti-depressant treatment</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>460</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>460</totalTarget>
      <exclusion>1. Pregnancy or breastfeeding
2. Background of severe psychiatric disorders: psychosis, paranoia, severe personality disorders, delusional thoughts
3. Existence of suicidal ideation or attempts
4. Two or more episodes of major depression, or one or more episodes that might require hospitalization
5. Patients who have received antidepressant medication in the past year
6. Patients with mental health problems who have been referred to psychiatric specialists for these reasons 
7. Substance abuse and/or drugs 
8. Treatment for Parkinson's disease or epilepsy
9. Temporal residents (plan to move in the next six months) 
10. Unable to communicate in Spanish or Catalan languages</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Major depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Half of the participants will be allocated to the intervention group and another half into the control group. This trial involves 23 doctors and 23 nurses from 12 primary care teams in Barcelona.

Intervention group: Implementation of a depression management protocol, based on evidence-based clinical guidelines, by the primary care nurse. This protocol includes pharmacological treatment with fluoxetine or another Selective Serotonin Re-uptake Inhibitor (SSRI), and the participants will have at least 6 appointments with the nurses during the 6 months of follow-up. At each visit, each patient will be informed about the disease and pharmacological treatment. In addition, the nurse will ask the patient about changes in mood and try to enhance compliance. Nurses will also provide emotional support. If the patient does not improve, he will be referred to his doctor. 

Control group: Six-month follow-up by family doctors. Family doctors will provides usual care management. They can prescribe fluoxetine or another SSRI. Participants will have at least 6 appointments with their doctor during the 6 months of follow-up.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17301-0</funderId>
      <contactId>Contact55262_17301</contactId>
      <sponsorId>Sponsor53830</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55262_17301">
    <title>Dr</title>
    <forename>María Isabel</forename>
    <surname>Fernández San Martín</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Lope de Vega 138</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08005</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53830">
    <organisation>Jordi Gol i Gurina Primary Care Research Institute (IDIAP Jordi Gol i Gurina) (Spain)</organisation>
    <website>http://www.idiapjgol.org/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Gran Via de les Corts Catalanes
587 àtic</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08007</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.452479.9</gridId>
    <rorId>https://ror.org/0370bpp07</rorId>
  </sponsor>
  <funder id="Funder17301-0">
    <name>Carlos III Health Institute of the Spanish Ministry of Health and Consumption (Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo), Health Research Fund   (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-12-14T00:00:00.000Z">46535923</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comprehensive care of infants: development and evaluation of an intervention strategy to enhance the promotion of health and quality of life of infants 2007 - 2010</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does a public health intervention aimed at promoting improved feeding practices delivered at home and facility levels increase the duration of exclusive breastfeeding in the first 6 months of life and reduce the prevalence of obesity among infants 6 - 12 months?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Prevalence of exclusive breastfeeding among infants up to 6 months of age
2. Prevalence of "recommended infant feeding practices" (continued breastfeeding and three complementary feeds/day) at 6 - 11 months
3. Prevalence of Body Mass Index (BMI)/age equal of greater than 2SD at 6 - 11 months</primaryOutcome>
      <secondaryOutcome>1. Diarrhoea and pneumonia in the 2 weeks before interview
2. Hospitalisations in the past year (and their cause)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. World Health Organization (WHO) Ethics Review Committee on the 21st November 2007 (ref: NCH07006)
2. Comite de Etica de la Investigacion (Cuba) on the 20th November 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46535923</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NCH 07006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>This is a cluster-randomised controlled trial of a public health intervention</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Cuba</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="081e3cb5-9509-44bc-b8c1-e475ee7fe854">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants are all infants living in the community area served by health centres included in the study.</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>12800</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>12800</totalTarget>
      <exclusion>The only exclusion criteria identified is the patient's refusal to participate.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Infant feeding practices</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Infant feeding</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group:
Promotion of improved feeding at the health facility and community levels using multiple channels:
1. Face-to-face
2. Community based media
3. Community groups

Control group:
Receives usual care.

Some of the details of the intervention, such as the frequency or duration of contact or exposure to the channels will only be fully defined at the end of the formative research phase. Interventions at the health facility level may include in-service training of the physicians and nurses in the health centres to improve their communication and counselling skills. Training of health workers and community counselors in this course will, we believe, be an important component of the intervention. The intervention may also include changes in management procedures to make them more compatible with family needs and expectations. Access to off-hour advice, privacy of consultations, triage and waiting time and characteristics of the waiting room are some of the examples of areas that may be considered for improvement. 

Interventions at the community level will make maximal use of appropriate existing channels either to be the primary sources of dissemination of messages or to re-enforce them. In addition to face-to-face communications individually or in group, the team will also consider the use of local mass media (e.g. local radio, pamphlets, banners, and posters), work and social clubs. The intervention will probably include the provision of information and the development with families of problem-solving approaches/strategies to deal with significant constraints. Face-to-face counselling will be one of the key components. Additional components may be included to remove existing barriers or promote actions that will support an increase in prevalence of a desired behaviour (for example, making breastfeeding counsellors available in the community for greater ease of access to counselling and support when mothers face a feeding difficulty).

Eighteen months after the introduction of the intervention, when we expect that the intervention will have been fully functional in all intervention clusters for at least 12 months, the post-intervention survey will be conducted to measure the impact on infants up to 12 months old. The length of exposure to the intervention will depend on the age of the infant and the period he/she has been residing in the community. Control clusters will continue to be provided the usual type of health care.

Contact details for Principal Investigator:
Dr Ibargollen Negrin Longina
Ministerio de Salud Publica
MCH Division
Calle 23 entre M y N. Vedado
Havana
Cuba 
Tel: +53 (0)7 833 2336</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17359-0</funderId>
      <contactId>Contact55320_17359</contactId>
      <sponsorId>Sponsor53889</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55320_17359">
    <title>Dr</title>
    <forename>Jose Carlos</forename>
    <surname>Martines</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 2634</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">martinesj@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53889">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int/child-adolescent-health</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Avenue Appia 20</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 2634</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mertinesj@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder17359-0">
    <name>World Health Organization (WHO) (Switzerland) (ref: NCH 07006)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2007-12-07T00:00:00.000Z">79227925</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Vitamin and mineral supplementation in reducing morbidity in Human Immunodeficiency Virus (HIV)-infected children in developing countries: an efficacy study</title>
      <scientificTitle/>
      <acronym>Mnuts/supps/HIV/children</acronym>
      <studyHypothesis>Micronutrient deficiencies contribute to immune dysfunction and can lead to increased infectious morbidity in Human Immunodeficiency Virus (HIV)-1-infected children. We hypothesised that micronutrient supplementation could reduce infectious morbidity in HIV-1-infected children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Relative frequency of adverse or serious infective episodes, or death.</primaryOutcome>
      <secondaryOutcome>1. Viral load and CD4 count changes
2. Biochemical variables such as micronutrient levels measures
3. Relative frequency of minor infective episodes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Research Ethics Committee (REC) of the University of Cape Town on 03/12/2001 (ref: RECRES 118/2001).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79227925</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind randomised, placebo-controlled clinical trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-04-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-11-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e26de706-133f-4f14-bb36-1f67fae659a5">
	  <name>Ambulatory Paediatrics</name>
	  <address/>
	  <city>Cape Town</city>
	  <state/>
	  <country>South Africa</country>
	  <zip>7700</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinically stable (not acutely ill)
2. Vertically transmitted HIV-1 infected children
3. Attending the Infectious Diseases Clinic at Red Cross Children's Hospital
4. Aged six months to six years</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Years" value="6.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>495</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>495</totalTarget>
      <exclusion>1. HIV-infected children aged less than six months
2. Children with an intercurrent infection or axillary temperature of more than 38°C
3. Children with any invasive opportunistic infection including tuberculosis
4. Children with bronchiectasis
5. Children who had received high dose vitamin A, trace elements or zinc supplements within the preceding eight weeks
6. Children recently hospitalised within the preceding six weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-04-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-11-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Micronutrient supplementation of HIV-1-infected children</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human Immunodeficiency Virus (HIV)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomised into one of the three arms:
Group A - placebo
Group B - trace element supplement
Group C - high dose zinc supplement (3 mg/kg elemental zinc)

Trial drugs are given orally daily over six months and children are seen monthly for 12 weeks from start to end of the study.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin and mineral supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15831-0</funderId>
      <contactId>Contact53771_15831</contactId>
      <sponsorId>Sponsor52324</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53771_15831">
    <title>Dr</title>
    <forename>Heloise</forename>
    <surname>Buys</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ambulatory Paediatrics
School of Child and Adolescent Health
Red Cross Children's Hospital
Klipfontein Road
Rondebosch</address>
      <city>Cape Town</city>
      <country>South Africa</country>
      <zip>7700</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52324">
    <organisation>Secure-The-Future Bristol-Myers Squibb (South Africa)</organisation>
    <website>http://www.bms.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bristol-Myers Squibb 
HIV Research Institute
47 van Buuren Road
Bedfordview</address>
      <city>Gauteng</city>
      <country>South Africa</country>
      <zip>2008</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+27 (0)11 4566459</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">richardwanlass@bms.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15831-0">
    <name>Secure-the-Future Bristol-Myers Squibb (South Africa) (ref: RES094/02)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-12-06T00:00:00.000Z">22412590</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pilot study for the treatment of heart failure with Pycnogenol</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pycnogenol, standardized French maritime pine bark extract, has shown beneficial effects on various cardiovascular health parameters such as blood pressure and cholesterol levels in both preclinical as well as clinical trials. The aim of this study is to investigate the effect of 200 mg daily of Pycnogenol on objective and subjective symptoms in patients with heart failure New York Heart Association (NYHA) status II.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Patients undergo tests for maximal workload and pressure-heart product at 0, 4, 8, and 12 weeks after enrollment. 

Maximal workload: As determined by a symptom-limited bicycle exercise test in the seated position. 
Pressure-heart rate product: Immediately after 2 min work at 50 W, systolic blood pressure and heart rate are recorded. Pressure-heart rate product is calculated by units of systolic blood pressure (mmHg) x heart rate per minute divided by 100.</primaryOutcome>
      <secondaryOutcome>Patients will report scores for dyspnea and fatigue for the foregoing 4 weeks upon enrollment (baseline) and repeat evaluation at 4, 8, and 12 weeks after enrollment. Symptom scores will be evaluated by asking patients about the severity of the following symptoms: 
1. Early fatigability
2. Dyspnea
3. General capability
4. Lassitude
5. Feeling depressed
6. Anxiety
 
Scores range from 0 = not present, 1 = occasionally mild, 2 = frequently mild, 3 = moderate, 4 = severe.
Blood analysis: Routine clinical chemistry in addition to the assays of BNP (NT-proBNP), C-Reactive Protein and troponin T.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethics Committee at Okuizumo Hospital in Shimane prefecture, Japan, on 24 May 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN22412590</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HF2007AM</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>12 week randomised, double-blind placebo-controlled matched pairs study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Japan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="45ceb3d9-4390-4acf-a1d9-cc5ea1d96bf1">
	  <name>Kyoto University Graduate School of Medicine</name>
	  <address/>
	  <city>Kyoto</city>
	  <state/>
	  <country>Japan</country>
	  <zip>606 8507</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients over 40 years of age with chronic congestive heart failure (NYHA class II), known for at least 6 months which were previously untreated or treated with a diuretic and/or a low dose of an ACE inhibitor. Patients must have an exercise capacity of at least 75 watts as assessed by seated bicycle ergometry.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. NYHA status I, III or IV
2. Treatment with digitalis within the previous 6 months
3. Exercise capacity of &gt;75 W for 2 min at the test during run-in
4. Unstable angina or myocardial infarction within the last 6 months
5. Atrial fibrillation or ventricular arrhythmia greater than or equal to Lown III
6. Cardiac valvular disease or hypertrophic cardiomyopathy
7. Significant hypertension or hypotension (&lt; 60 mmHg or greater than or equal to 105 mmHg diastolic or &lt; 90 mmgH or &gt; 175 mmHg systolic)
8. Electrolyte disturbances, hyperuricemia, hypovolemia
9. Impaired renal function (creatinine &gt;1.8 mg/dL) or hepatic function
10. Obstructive airways disease 
11. Insulin-dependent diabetes
12. Malignant or other serious disease
13. Hypersensitivity to study drug
14. Pregnancy, unreliable contraception, breast-feeding mothers
15. Participation in another clinical trial within the last 6 weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Heart failure</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Heart failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>200 mg Pycnogenol (standardized extract of French maritime pine bark) or placebo for 12 weeks. Patients receiving diuretics before enrollment should continue usage and not change dose/intake intervals. Drug intake will be controlled and any unwanted effect reported at each visit.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pycnogenol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16783-0</funderId>
      <contactId>Contact54741_16783</contactId>
      <sponsorId>Sponsor53297</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54741_16783">
    <title>Dr</title>
    <forename>Akira</forename>
    <surname>Matsumori</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kyoto University Graduate School of Medicine
Department of Cardiovascular Medicine
54 Kawahara-cho Shogoin
Sakyo-ku</address>
      <city>Kyoto</city>
      <country>Japan</country>
      <zip>606 8507</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53297">
    <organisation>Kyoto University (Japan)</organisation>
    <website>http://www.kyoto-u.ac.jp/index-e.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr Akira Matsumori
Kyoto University Graduate School of Medicine
Department of Cardiovascular Medicine
54 Kawahara-cho Shogoin
Sakyo-ku
</address>
      <city>Kyoto</city>
      <country>Japan</country>
      <zip>6068507</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.258799.8</gridId>
    <rorId>https://ror.org/02kpeqv85</rorId>
  </sponsor>
  <funder id="Funder16783-0">
    <name>Kyoto University, Cardiomyopathy and Myocarditis Research Fund (Japan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-28T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2007-11-27T00:00:00.000Z">11132850</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of oral intra-dialysis supplement  in haemodialysis patients with malnutrition</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Nutritional support in the form of oral supplement during the sessions of haemodilaysis improves the nutritional status of the patients, increases the oral food intake, improves the functional situation and quality of life and reduces the morbidity and mortality.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following data will be collected at the beginning of the study (basal), and at three and six months (final):
1. Serum albumin, measured by blood analysis
2. Prealbumin, measured by blood analysis</primaryOutcome>
      <secondaryOutcome>Collected at the beginning of the study (basal), collected at the beginning of the study (basal), and at three and six months (final):
1. Prevalence of malnutrition
2. Anthropometric nutritional parameters
3. Analytical nutritional parameters
4. Body composition (collected at the beginning of the study [basal] and at the sixth month [final] only)
5. Quality of life
6. Functional scale
7. Appetite
8. Oral food intake. Later on this information will be passed through a special program in order to calculate the total caloric intake and food composition (protein, carbohydrates and fat including saturated, mono- and poly-unsaturated fat)
9. Hospital admissions (collected as and when these events happen)
10. Mortality (collected as and when these events happen)
11. Morbidity and mortality rate (collected as and when these events happen)

Measurements taken to assess these outcomes will include:
1. Anthropometric measures: dry body weight, Body Mass Index (BMI), Brachial Muscle Circumference (BMC), triceps skin fold
2. Blood tests: Complete Blood Count (CBC), urea prior and post dialysis, creatinine, electrolytes, lipid profile, serum iron, ferritin, vitamin B12, folic acid, Parathyroid Hormone (PTH), calcium, phosphate, vitamin D3, transferrin, albumin, prealbumin, bicarbonate (HCO3) prior and post dialysis, insulin, fasting blood sugar, Homeostasis Model Assessment (HOMA) index, C-Reactive Protein (CRP)
3. Body composition: electrical Bioimpedance Analysis (BIA) monofrequency
4. Nutritional assessment: SGA and MIS
5. Questionnaires: charlson index, karnofsky scales (evaluated by interviewing each patient and by checking his medical history report at the beginning of the study, third month and sixth month), 36-item Short Form health survey (SF-36) and 8-item Council on Nutrition Appetite Questionnaire (CNAQ)
6. Dietary recall (48 hours): day of dialysis and day off will be collected from patients interview</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethical Committee of Clinical Investigation of the Hospital Clinico San Carlos on the 24th January 2007 (ref: 1.2/07). Signed by secretary of the committee Dr. M. Garcia Arenillas.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11132850</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>06/178</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled single-blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4a1294e2-0024-483c-b430-5b14eb4b4e31">
	  <name>Avenida Marques de Corbera 6, 6d</name>
	  <address/>
	  <city>Madrid</city>
	  <state/>
	  <country>Spain</country>
	  <zip>28017</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients over 18 years old 
2. Maintained haemodialysis (at least 6 months on dialysis)
3. Malnutrition criteria (Subjective Global Assessment [SGA] grade B or C or Malnutrition Inflammation Score [MIS] score greater than 8) and at least  two altered analytical parameters (albumin less than 3.7 g/dl, prealbumin less than 30 g/l, total cholesterol less than 200 mg/dL with C-Reactive Protein [CRP] within normal range)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Lack of  signed consent 
2. Difficulty in understanding Spanish language
3. Patients diagnosed of cancer except skin cancer
4. Patients went through surgical operation in the last three months 
5. Patients with Dementia or Alzheimer disease</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malnutrition</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Malnutrition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Specific oral supplement formula for patients on haemodialysis (Nepro) plus dietetic consultation for the case group, versus only dietetic consultation for the control group. 
The formula is Nepro, a product of Abbott laboratory. Dosage is 236 ml in each session of haemodialysis, providing 472 kcal and 7 g of protein per 100 ml. 

Duration of intervention: 6 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17255-0</funderId>
      <contactId>Contact55216_17255</contactId>
      <sponsorId>Sponsor53782</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55216_17255">
    <title>Dr</title>
    <forename>Waeel Ibrahim</forename>
    <surname>Alkrekshi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Avenida Marques de Corbera 6, 6d</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28017</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 91 62 78 88 95 0</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krekshi@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53782">
    <organisation>Foundation of Metabolic Studies (Fundacion de estudios metabolicos) (Spain) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Hospital Clinico san Carlos 
C/ Martin Lagos S/N</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 91 33 03 64 3</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krekshi@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17255-0">
    <name>Foundation of Metabolic Studies (Fundacion de estudios metabolicos) (Spain) - in cooperation with the Hospital Clinco San Carlos (Spain), Department of Endocrinology and Nutrition</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-22T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-11-22T00:00:00.000Z">38444899</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of a Cognitive Behavioural group Therapy (CBT) for compulsive buying disorder</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Disorder specific group Cognitive Behavioural Therapy (CBT) can improve the compulsive buying behaviour.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Compulsive Buying Scale (CBS)
2. Yale-Brown Obsessive Compulsive Scale - Shopping Version (Y-BOCS-SV)
3. German Compulsive Buying Scale (G-CBS)

All participants were assessed at baseline. Participants assigned to CBT were assessed at the end of treatment and at the end of a 6-months follow-up period. Individuals assigned to the WLC were reassessed 12 weeks after the baseline assessment. All assessments were conducted by research staff members who remained blind to the treatment assignment throughout the study. Participants completed all self-report questionnaires during the assessment visits.</primaryOutcome>
      <secondaryOutcome>1. Symptom Check-List-90-R (SCL-90-R)
2. Barratt Impulsiveness Scale (BIS-11)
3. Saving Inventory - Revised (SI-R)

All participants were assessed at baseline. Participants assigned to CBT were assessed at the end of treatment and at the end of a 6-months follow-up period. Individuals assigned to the WLC were reassessed 12 weeks after the baseline assessment. All assessments were conducted by research staff members who remained blind to the treatment assignment throughout the study. Participants completed all self-report questionnaires during the assessment visits.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Ethics Committee of the University Hospital of Erlangen (Germany) on the 27th August 2003 (ref: 3008).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38444899</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, efficacy study comparing CBT with waiting list control.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4f9e568b-66e2-4c36-97f4-4c77e2eb42ee">
	  <name>Department of Psychosomatic Medicine and Psychotherapy</name>
	  <address/>
	  <city>Erlangen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-91054</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Current compulsive buying problems according to the criteria of McElroy et. al. (1994)
2. Aged 18 and over</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Active suicidal ideation
2. Current mania</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Compulsive buying disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Adult personality disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This trial is a randomised controlled trial comparing a treatment group with a waiting list control group (2 arms). Because of logistical difficulties a simultaneous conduction of groups was not feasible in this monocentric study. Patients were assigned to groups upon enrolment, which were subsequently randomised to one of two conditions. Thirty-one participants were assigned to one of five CBT groups, and 29 individuals to one of five Waiting List Control (WLC) groups. Participants were blind to the randomisation. 

Intervention:
12-weekly outpatient disorder specific group CBT-sessions specifically aiming at interrupting and controlling the problematic buying behaviour, establishing healthy purchasing patterns, restructuring maladaptive thoughts and negative feelings associated with shopping and buying, and developing healthy coping skills. 

Control:
Waiting list control. 

Treatment lasted 12 weeks with one 90-minutes session per week. Groups were conducted with 5 - 8 participants. Follow-up was for 6 months after finishing the treatment for all participants.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17868641 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2ce6bf78-f597-49da-913e-394ef7dc99f1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17868641"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16920-0</funderId>
      <funderId>Funder16920-1</funderId>
      <contactId>Contact54881_16920</contactId>
      <sponsorId>Sponsor53444</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54881_16920">
    <title>Dr</title>
    <forename>Astrid</forename>
    <surname>Mueller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychosomatic Medicine and Psychotherapy
University Hospital of Erlangen
Schwabachanlage 6</address>
      <city>Erlangen</city>
      <country>Germany</country>
      <zip>D-91054</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)9131 85 34890</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">astrid.mueller@uk-erlangen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53444">
    <organisation>University Hospital of Erlangen (Germany)</organisation>
    <website>http://www.elan.uk-erlangen.de/e404/index_ger.html</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Erlanger Leistungsbezogene Anschubfinanzierung und Nachwuchsforderung (ELAN) fund 
Universitatsstrasse 40</address>
      <city>Erlangen</city>
      <country>Germany</country>
      <zip>D-91054</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)9131 85 23708</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">annette.pfeiffer@zuv.uni-erlangen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411668.c</gridId>
    <rorId>https://ror.org/0030f2a11</rorId>
  </sponsor>
  <funder id="Funder16920-0">
    <name>University Hospital of Erlangen (Germany) - Erlanger Leistungsbezogene Anschubfinanzierung und Nachwuchsforderung (ELAN) fund</name>
    <fundRef/>
  </funder>
  <funder id="Funder16920-1">
    <name>Bavarian Savings Bank Foundation (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-15T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-11-15T00:00:00.000Z">40223079</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of artesunate and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for the treatment of vivax malaria in Nangarhar, Takhar and Faryab provinces, Afghanistan</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Monitor efficacy and safety of artesunate and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for the treatment of vivax malaria.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. To measure the clinical and parasitological efficacy of artesunate and sulfadoxine-pyrimethamine among patients aged above six months suffering from uncomplicated falciparum malaria and chloroquine for vivax malaria, by determining the proportion of patients with:
1.1. Early Treatment Failure (ETF)
1.2. Late Clinical Failure (LTF)
1.3. Late Parasitological Failure (LPF)
1.4. Adequate Clinical and Parasitological Response (ACPR) 
As indicators of efficacy
2. To differentiate recrudescences from new infections by the Polymerase Chain Reaction (PCR) analysis
3. To evaluate the incidence of adverse events</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. Ministry of Public Health Afghanistan on the 15th September 2007
2. World Health Organization (WHO) Ethics Review Committee (ERC) on the 13th November 2007 (ref: RPC 243)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN40223079</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC243</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>One arm non-comparative study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Afghanistan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9b1172ad-0422-4c61-b991-7967ad7d478f">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age above 6 months
2. Mono-infection with P. falciparum or P. vivax
3. Parasitaemia, 1000 - 100,000 asexual forms per µl for falciparum malaria and above 250 asexual forms per µl for vivax malaria
4. Axillary temperature of 37.5°C or oral/rectal temperature of 38°C
5. Ability to swallow oral medication
6. Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule
7. Informed consent from the patient or from a parent or guardian in case of children</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Presence of general danger signs among children less than 5 years old or other signs of severe and complicated falciparum malaria according to current WHO definitions (see Annex 1)
2. Mixed or mono-infection with another Plasmodium species
3. Presence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviation or less than 70% of the median of the National Center for Health Statistics [NCHS]/WHO normalised reference values, or who has symmetrical oedema involving at least the feet or who has a Mid Upper Arm Circumference [MUAC] less than 110 mm)
4. Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhoea with dehydration, etc.), or other known underlying chronic or severe diseases (e.g. cardiac, renal, hepatic diseases, Human Immunodeficiency Virus [HIV]/Acquired Immune Deficiency Syndrome [AIDS])
5. History of hypersensitivity reactions to any of the drug(s) being tested or used as alternative treatment
6. Positive pregnancy test or lactating (if adults included)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Artesunate (12 mg/kg) and sulfadoxine (25 mg/kg single dose) - pyrimethamine (1.25 mg/kg single dose) over 3 days for falciparum malaria
2. Chloroquine 25 mg/kg over 3 days for vivax malaria

Contact details for Principal Investigator: 
Dr Ghulam Rahim Awab 
District/Phase - 4
Jalalabad City 
Nangarhar 
Afghanistan
Tel: +93 (0)70 004 4853
Email: awabgr@yahoo.com</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Artesunate, sulfadoxine-pyrimethamine, chloroquine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17277-0</funderId>
      <contactId>Contact55238_17277</contactId>
      <sponsorId>Sponsor53806</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55238_17277">
    <title>Dr</title>
    <forename>Pascal</forename>
    <surname>Ringwald</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
Avenue Appia 20</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3469</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ringwaldp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53806">
    <organisation>World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int/malaria/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Avenue Appia 20</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3469</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ringwaldp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder17277-0">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">68179235</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Treatment of itch with naltrexon in patients with burns</title>
      <scientificTitle>Treatment of itch with naltrexone in patients with burns: an explorative, randomised, double blind, placebo-controlled, cross-over clinical trial</scientificTitle>
      <acronym>BITE (Burns Itch TreatmEnt study)</acronym>
      <studyHypothesis>The primary objective of this study is to evaluate the efficacy and safety of naltrexone in the treatment of itch in patients with burn wounds.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mean itch intensity score at endpoint, defined as the mean of the last 7 diary entries while the patient is receiving study medication. The percentage change in itch intensity score from baseline is calculated as:
1 - (mean itch intensity score end point/mean itch intensity score baseline) x 100%</primaryOutcome>
      <secondaryOutcome>1. Additional aspects of itch (e.g. frequency, duration) 
2. The effect of treatment as perceived by the patient, pain, and various aspects of anxiety and sleep:
2.1. Itch presence, measured at baseline 1
2.2. Demographics, measured at baseline 1	 
2.3. Burn injury characteristics, measured at baseline 1
2.4. Polymorphism µ-receptor (DNA), measured at intervention week 2
2.5. Blood plasma level, measured at intervention week 2 and intervention week 4
2.6. Scar: 
2.6.1. Patient and Observer Scar Assessment Scale (POSAS), measured at baseline 1 and intervention week 4
2.6.2. Dermaspect, measured at baseline 1 and intervention week 4
2.7. Itch: 	
2.7.1. Visual Analogue Scale (VAS) measured daily throughout treatment
2.7.2. Body-Image Ideals Questionnaire (BIQ), measured at baseline 1, intervention week 1, intervention week 2, baseline 2, intervention week 3, intervention week 4
2.8. Sleep:	
2.8.1. Visual Analogue Scale (VAS) measured daily throughout treatment	
2.8.2. Medical Outcomes Study (MOS)-Sleep, measured at baseline 1, intervention week 1, baseline 2, intervention week 3	
2.9. Pain: Visual Analogue Scale (VAS) measured daily throughout treatment	
2.10. Anxiety: Hamilton Anxiety and Depression Scale (HADS), measured at baseline 1, intervention week 1, baseline 2, intervention week 3	
2.11. Treatment effect: Patient Global Impression of Change (PGIC), measured at intervention 2 and intervention 4
2.12. Adverse Drug Reaction, measured daily during the intervention and wash out periods

Timepoints:
Baseline 1: 7 days
Intervention week 1: 7 days
Intervention week 2: 7 days
Wash-out 1: three days
Baseline 2: 7 days
Intervention week 3: 7 days
Intervention week 4: 7 days
Wash-out 2: 3 days</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics board (Stichting Beoordeling Ethiek Biomedisch Onderzoek, Medisch Ethische toetsingscommissie [METC Assen]) on the 4th July 2007 (ref: MZH 2007-20).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68179235</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo controlled, crossover group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="82152da2-0c53-4642-aff0-31c64f0e709b">
	  <name>Martini Hospital</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RM</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Eligible for inclusion are patients:
1. With (almost) healed burns who have been admitted to the burn centre
2. Who are 18 years of age or older with itch 4 - 6 weeks post burn</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Patients will be excluded when meeting one of the following exclusion criteria: 
1. Total Body Surface Area (TBSA) of more than 20%
2. Liver insufficiency (in this study that means more than two times the normal range of the liver enzymes: Aspartate Aminotransferase [ASAT] greater than 80 U/L and/or Alanine Aminotransferase [ALAT] greater than 80 U/L and/or Alkaline Phosphatase [AP] greater than 250U/L and/or Gamma Glutamyl Transpeptidase [GGT] greater than 100U/L)
3. Acute hepatitis
4. History of drug/alcohol abuse
5. Known sensitivity for any of the following substances: naltrexonehydrochloride, lactose monohydrate, crospovidone, powder cellulose, microcrystalline cellulose, colloid silicon dioxide, magnesium stearate, hypromellose, macrogole 4000, Titanium dioxide (E171), Black iron oxide (E172), Red iron oxide (E172), Yellow iron oxide (E172), carboxymethylamylum sodium type A, precirole
6. Pregnant
7. Breast feeding
8. Having used opioids 10 days prior to the start of treatment
9. Using itch medication other than the study medication and unwilling to stop
10. Psychiatric disorder
11. Other disease associated with itch (e.g. eczema, atopic dermatitis, cholestatic pruritus)
12. Insufficiently proficient in Dutch to give informed consent and/or fill out the questionnaires</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Burns</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Burns</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will take either naltrexone or placebo for two weeks and are randomised to start with one or the other. Before the two treatment periods a baseline measurement of 7 days will be done. In between the two treatment periods there will be a wash-out period of 3 days. The naltrexone dose will be 50 mg once daily. On the first day patients will receive two times 25 mg of naltrexone with at least one hour in between. The procedure on the first day will be mimicked where the placebo is concerned.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16867-0</funderId>
      <contactId>Contact54825_16867</contactId>
      <sponsorId>Sponsor53382</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54825_16867">
    <title>Dr</title>
    <forename>A.</forename>
    <surname>Wieringa</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Martini Hospital
Department of Pharmacy
P.O. Box 30033</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 524 5771</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andre.wieringa@mzh.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53382">
    <organisation>Martini Hospital (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Surgery
P.O. Box 30033</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.416468.9</gridId>
    <rorId>https://ror.org/017b69w10</rorId>
  </sponsor>
  <funder id="Funder16867-0">
    <name>Association of Dutch Burn Centres (ADBC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-14T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">91751187</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bowel Preparation for elective Left-Sided Colonic Surgery</title>
      <scientificTitle/>
      <acronym>BP LSCS</acronym>
      <studyHypothesis>The objective of this study is to ascertain the best method of bowel preparation, prior to elective left-sided colonic surgery in terms of patient comfort and surgical efficacy. Sodium phosphate enemas (Colex) and bisacodyl (tablet and suppository) are to be compared. The occurrence of infections (wound, peritonitis) and anastomotic leaks will be monitored.

Null hypotheses are:
1. Patients in both groups experience pain and discomfort equally
2. The surgeon finds no difference in the condition of the left hemicolon intraoperatively
3. No difference in incidence of infection is found
4. No difference in incidence of anastomotic leaks is found</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Questionnaires will be used to assess the opinions of patients and surgeons. The parameters are recorded in a five point scale.</primaryOutcome>
      <secondaryOutcome>The occurrence of infection (wound or peritonitis) and anastomotic leaks is determined by standard postoperative care and is established when the clinical diagnosis is made.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the local ethics committee (Medisch Ethische Toetsingscommissie Atrium MC - Maaslandziekenhuis) on the 30th October 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91751187</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NL14234.096.06</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, single blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-06T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e5e425f8-a382-41d5-8089-433c45252b58">
	  <name>Atrium Medisch Centrum Heerlen</name>
	  <address/>
	  <city>Heerlen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6401 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The study population will consist of adult patients undergoing elective left-sided colonic surgery. Left-sided colonic surgery includes the following procedures: 
1. Left hemicolectomy
2. Sigmoid resection
3. Low anterior resection
4. Hartmann procedure
5. Reconstruction of colostomy
6. Abdominoperineal resection by Miles

Procedures on the transverse colon will also be included as this can result intraoperatively in a left hemicolectomy. Reasons for surgery vary, examples are malignancy, diverticulitis, Crohns disease and ulcerative colitis.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Exclusion criteria are:
1. Use of Klean-Prep
2. Contra-indications for use of bisacodyl and Colex
3. Emergency procedures</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bowel preparation, sodium phosphate enema, solonic surgery, bisacodyl</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Colonic surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Interventions in the bisacodyl group:
1. Evening before surgery (8 p.m.) - bisacodyl tablet 5 mg, four tablets, oral administration 
2. Morning of surgery (6 a.m.) - bisacodyl suppository 10 mg, one suppository, rectal administration

Intervention in the Colex group:
1. Evening before surgery (8 p.m.) - Colex 133 ml, enema, rectal administration
2. Morning of surgery (6 a.m.) - Colex 133 ml, enema, rectal administration</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Bisacodyl, sodium phosphate (Colex)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16225-0</funderId>
      <contactId>Contact54180_16225</contactId>
      <sponsorId>Sponsor52734</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54180_16225">
    <title>Dr</title>
    <forename>C</forename>
    <surname>van der Leeuw</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Atrium Medisch Centrum Heerlen
Chirurgie</address>
      <city>Heerlen</city>
      <country>Netherlands</country>
      <zip>6401 CX </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)64 847 7103</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">C.vanderLeeuw@student.unimaas.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52734">
    <organisation>Atrium Medisch Centrum (The Netherlands)</organisation>
    <website>http://www.atriummc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 4446</address>
      <city>Heerlen</city>
      <country>Netherlands</country>
      <zip>6401 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.414040.5</gridId>
    <rorId>https://ror.org/0367sye10</rorId>
  </sponsor>
  <funder id="Funder16225-0">
    <name>Atrium Medisch Centrum (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-02-23T00:00:00.000Z">13256080</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase II study to investigate the effect of Glivec® (imatinib mesylate, formerly known as STI571) in patients with inoperable medullary thyroid carcinoma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>In the pathogenesis of medullary thyroid carcinoma a mutation of the rearranged during transfection (RET) tyrosine kinase system plays an essential role. In animal models the tyrosine kinase inhibitor imatinib showed tumor regression. So a phase II study in patients with progressive medullary thyroid carcinoma with imatinib may open new treatment possibilities.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary objective is to determine the objective response rate (partial and complete responses) in subjects with advanced medullary thyroid carcinoma.</primaryOutcome>
      <secondaryOutcome>1. To determine the time to tumour progression
2. To evaluate overall survival
3. To evaluate the safety profile of Glivec® in advanced medullary thyroid carcinoma</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13256080</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CSTI571BNL07; METC 03-044</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational phase II study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-07-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6c01d901-b34b-4ed8-bc1c-28ab1f3c4bf2">
	  <name>University Medical Centre Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients over 18 years of age
2. The subject has advanced histologically proven medullary thyroid cancer. Advanced disease is defined as locally recurrent disease or metastatic disease that is not amenable to curative resection. The subject must have measurable disease.
3. The subject has not received anti-tumor radiotherapy or chemotherapy therapy within four weeks (six weeks for nitrosourea, mitomycin-C or any antibody therapy) of the start of imatinib administration
4. The subject has an Eastern Cooperative Oncology Group (ECOG) performance score of zero to two  
5. Adequate end organ function, defined as the following: 
5.1. Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)
5.2. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than 2.5 x ULN
5.3. Creatinine less than 1.5 x ULN
5.4. Absolute neutrophil count (ANC) more than 1.5 x 10^9/L
5.5. Platelets more than 100 x 10^9/L
6. Female patients of childbearing potential must have negative pregnancy test within seven days before initiation of study drug dosing. Postmenopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to three months following discontinuation of study drug.
7. Life expectancy of more than three months (in the absence of any intervention)
8. The subject has voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent prior to any study specific procedures</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15</totalTarget>
      <exclusion>1. The subject is less than five years free of another primary malignancy except: 
1.1. If the other primary malignancy is not currently clinically significant nor requiring active intervention, or 
1.2. If the other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ
2. The subject is with known brain metastases
3. The subject has received any other investigational agents within 28 days of first day of study drug dosing
4. The subject has a current history of a class three to four cardiovascular disability status in accordance with the New York Heart Association Functional Classification:
4.1. Class three is defined as marked limitation of physical activity, comfortable at rest, but less than ordinary activity causes fatigue or dyspnea
4.2. Class four is defined as being unable to carry on any physical activity without symptoms and symptoms are present even at rest. Also, if any physical activity is undertaken, symptoms are increased
5. Female patients who are pregnant or breast-feeding
6. Patient has another severe and/or life-threatening medical disease
7. The subject has an acute or known chronic liver disease (e.g., chronic active hepatitis, cirrhosis)
8. The subject has a known diagnosis of human immunodeficiency virus (HIV) infection
9. The subject has received chemotherapy within four weeks (six weeks for nitrosourea, mitomycin-C or any antibody therapy) prior to study entry
10. The subject had a major surgery within two weeks prior to study entry
11. The subject uses therapeutic anticoagulation with warfarins. Low-molecular weight heparin (e.g. Fragmin®) or heparin is permitted.
12. The subject with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-07-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-11T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Medullary thyroid carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Thyroid carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Oral treatment with 600 - 800 mg imatinib daily.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Imatinib mesylate (Glivec®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17579194 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2a509938-e8a4-44aa-a743-ad3ef43c3380" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17579194"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16197-0</funderId>
      <contactId>Contact54152_16197</contactId>
      <sponsorId>Sponsor52706</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54152_16197">
    <title>Dr</title>
    <forename>B A</forename>
    <surname>Zonnenberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht (UMCU)
Department of Medical Oncology
Heidelberglaan 100</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 250 6308</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">B.Zonnenberg@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52706">
    <organisation>University Medical Centre Utrecht (UMCU) (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder16197-0">
    <name>Novartis Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-29T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-01-04T00:00:00.000Z">10862635</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pilot study of efficacy of anakinra in acute gouty arthritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Treatment with anakinra will decrease the signs and symptoms of acute gout.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pain of arthritis
2. Signs of arthritis</primaryOutcome>
      <secondaryOutcome>Biological markers of inflammation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics committee approval is pending, approval expected in January 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10862635</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open label pilot study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8209f180-fa32-4d47-a7be-2b06811eabd2">
	  <name>Rheumatology Service</name>
	  <address/>
	  <city>Lausanne</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>1011</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Acute gout as defined by American College of Rheumatology (ACR) criteria
2. Acute arthritis due to gout which is unresponsive to conventional therapy with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), colchicine or steroids
3. Patients with acute gout who have had side effects or intolerance to either NSAIDs, colchicine or steroids</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Patients with on-going or untreated infectious diseases 
2. Patients with rheumatoid arthritis, lupus or vasculitis
3. Patients concurrently treated with anti-Tumour Necrotising Factor (TNF) therapies 
4. Patients with active cancer</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute gout</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Acute gout</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment with 100 mg anakinra daily subcutaneously for three days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Anakinra</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17352828 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="94ae020d-57fe-44c5-86c7-dedff977db67" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17352828"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15830-0</funderId>
      <contactId>Contact53770_15830</contactId>
      <sponsorId>Sponsor52323</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53770_15830">
    <title>Prof</title>
    <forename>Alexander</forename>
    <surname>So</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rheumatology Service
Centre Hospitalier Universitaire Vaudois (CHUV)
Av Pierre Decker</address>
      <city>Lausanne</city>
      <country>Switzerland</country>
      <zip>1011</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52323">
    <organisation>University Hospital Complex of Vaud (Centre Hospitalier Universitaire Vaudois [CHUV]) (Switzerland)</organisation>
    <website>http://www.chuv.ch/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Rheumatology
Department of Medicine
University of Lausanne</address>
      <city>Lausanne</city>
      <country>Switzerland</country>
      <zip>1011</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)21 314 14 50</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">secretariat.so@chuv.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.8515.9</gridId>
    <rorId>https://ror.org/05a353079</rorId>
  </sponsor>
  <funder id="Funder15830-0">
    <name>Service of Rheumatology of the Centre Hospitalier Universitaire, Vaudois (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-11-29T00:00:00.000Z">05215453</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of rosiglitazone, compared to sulphonylurea, on endothelial function in Chinese patients with type two diabetes</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Rosiglitazone improves endothelial function independent of its effect on glycemic control
2. Rosiglitazone affects soluble receptor of advanced glycation end products independent of its effect on glycemic control</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Changes in endothelial function in patients with type two diabetes</primaryOutcome>
      <secondaryOutcome>1. Changes in blood pressure and metabolic parameters such as C-reactive protein. 
2. Changes in serum soluble Receptor for Advanced Glycation End products (sRAGE) and advanced glycation end products.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster on the 19th March 2004 (ref: UW 04-045 T/367).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05215453</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HKCTR-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hong Kong</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4c924cb5-d2de-4e32-b345-b444606abd22">
	  <name>The University of Hong Kong</name>
	  <address/>
	  <city>Pokfulam</city>
	  <state/>
	  <country>Hong Kong</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Chinese men and women aged 30 to 70 years
2. Type two diabetes (defined by the World Health Organization [WHO] criteria) diagnosed after 30 years of age
3. On diet with/without sulphonylurea (less than or equal to half-maximum dose) with/without metformin for at least six months
4. No change in anti-diabetic, lipid lowering and anti-hypertensive in preceding 12 weeks
5. Body Mass Index (BMI) more than or equal to 23 and less than or equal to 35 kg/m^2
6. Systolic blood pressure less than or equal to 160 mmHg and diastolic blood pressure less than or equal to 90 mmHg
7. HbA1c levels between 7.5 and 10.5% inclusively (normal less than or equal to 6.1%) on at least two occasions in the past three months
8. Female patients must be post-menopausal (i.e. more than six months without menstrual period), surgically sterilised, or using hormonal contraceptives or intrauterine devices</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>68</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68</totalTarget>
      <exclusion>1. Pregnancy or lactation
2. Any clinically significant abnormality identified on the screening physical examination, laboratory tests, or electrocardiogram which, in the judgement of the investigator, would preclude the safe completion of the study
3. Use of anti-diabetic drugs other than metformin or sulphonylurea within 12 weeks
4. Use of any investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication
5. Patients with a documented history of significant hypersensitivity to any drugs including thiazolidinedione and sulphonylurea (e.g., difficulty in swallowing or breathing, or tachycardia)
6. Active alcohol or drug abuse within the last six months
7. Presence of clinically significant renal or hepatic disease:
7.1. Serum creatinine above Upper Normal Range (UNR) (creatinine more than 128 umol/L for males and more than 107 umol/L for females)
7.2. Proteinuria more than 1 gm/day
7.3. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), total bilirubin, or alkaline phosphatase more than two times above UNR
8. Significant anaemia (haemoglobin less than 11 g/dl for males or less than 10 g/dl for females)
9. Patients with haemoglobinopathies
10. Leukocyte count less than 3.0 x 10^9/L or platelet count less than 120 x 10^9/L
11. Patients with severe angina, coronary insufficiency, heart failure (New York Heart Association [NYHA] class III or IV), or history of cardiovascular event in the past six months
12. Patients with electrocardiographic evidence of left ventricular hypertrophy based upon the maximal voltage of Sv1 plus the maximal voltage of Rv5 or Rv6 more than 3.5 mV and ST-T segment changes
13. Symptomatic diabetic neuropathy of sufficient severity to require treatment for control of symptoms (e.g. painful peripheral neuropathy, symptomatic orthostatic hypotension, urinary retention, pedal ulcers, gastric stasis, etc.)
14. Patients with history of psychiatric illness</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type two diabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised to receive add-on therapy with either rosiglitazone 4 mg or glibenclamide 5 mg (or gliclazide 80 mg) daily while keeping the doses of their usual anti-diabetic agents constant. After four weeks, the doses of the add-on therapy were doubled in subjects with fasting blood glucose level greater than 8.0 mmol/l and without symptomatic or asymptomatic hypoglycemia defined as blood glucose level less than 3.0 mmol/l. The dosages of all anti-diabetic agents were then kept constant for another 20 weeks.

There was no washout period and all study medications were administered orally.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosiglitazone and sulphonylurea</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17639302 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="6123f1f0-fd23-4e64-9de6-95404d331462" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17639302"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15807-0</funderId>
      <funderId>Funder15807-1</funderId>
      <contactId>Contact53747_15807</contactId>
      <sponsorId>Sponsor52299</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53747_15807">
    <title>Prof</title>
    <forename>Karen</forename>
    <surname>Lam</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>The University of Hong Kong
Queen Mary Hospital</address>
      <city>Pokfulam</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52299">
    <organisation>Hong Kong University Research Committee (Hong Kong)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>7/F., Shui On Centre
6-8 Harbour Road</address>
      <city>Wanchai</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.194645.b</gridId>
    <rorId>https://ror.org/02zhqgq86</rorId>
  </sponsor>
  <funder id="Funder15807-0">
    <name>Hong Kong University Research Committee (Hong Kong) (project no. HKU 7637/05M)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15807-1">
    <name>HK Innovation and Technology Support Programme (Hong Kong) (project no. ITS/048/03)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-11-03T00:00:00.000Z">75663024</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>BAsel Stent KostenEffektivitaets Trial (Basel Stent cost-effectiveness trial)</title>
      <scientificTitle/>
      <acronym>BASKET (BAsel Stent KostenEffektivitaets Trial)</acronym>
      <studyHypothesis>Drug Eluting Stents (DES) are not cost-effective in a real world setting when compared to bare metal stents.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Six month cost-effectiveness with effectiveness defined as reduction of major adverse cardiac events - i.e., cardiac death, non-fatal myocardial infarction and target vessel revascularisation.</primaryOutcome>
      <secondaryOutcome>1. Mortality from other cause, target vessel ischemia by myocardial perfusion Single Photon Emission Computed Tomography (SPECT).
2. Effectiveness of DES in patients with myocardial infarction and saphenous vein graft disease. 
3. Cost-effectiveness as defined above after 18 and 36 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the local ethics committee of the University of Basel, March 27, 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75663024</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a0aeba82-f29d-4e72-8396-2a0c41b87555">
	  <name>Cardiology Department</name>
	  <address/>
	  <city>Basel</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-4031</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Coronary artery disease suitable for interventional therapy.

All patients referred for cardiac catheterisation and subsequent Percutaneous Coronary Intervention (PCI) irrespective of clinical indication, who are able to provide written informed consent.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>826</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>826</totalTarget>
      <exclusion>1. In-stent-restenosis
2. Target vessel diameter equal to or greater than 4 mm
3. No informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary artery disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Coronary artery disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>PCI in a real world setting (chronic and acute disease). Patients randomised 2:1 to drug eluting versus bare metal stents.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16154019 Results
2007 Other publications in https://pubmed.ncbi.nlm.nih.gov/17980734 -month cost-effectiveness analysis:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="caafc7de-7862-4d1f-82d5-708af2be21aa" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16154019"/>
	<description>Results</description>
	<productionNotes/>
      </output>
      <output id="7d0a1e1f-460a-453d-9b2d-132a7eaa8735" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2007-11-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17980734"/>
	<description>-month cost-effectiveness analysis:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15761-0</funderId>
      <funderId>Funder15761-1</funderId>
      <contactId>Contact53699_15761</contactId>
      <sponsorId>Sponsor52253</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53699_15761">
    <title>Prof</title>
    <forename>Matthias</forename>
    <surname>Pfisterer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cardiology Department
University Hospital
Petersgraben 4</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>CH-4031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52253">
    <organisation>University Hospital Basel (Switzerland)</organisation>
    <website>http://www.universitaetsspital-basel.ch/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Petersgraben 4</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>CH-4031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410567.1</gridId>
    <rorId>https://ror.org/04k51q396</rorId>
  </sponsor>
  <funder id="Funder15761-0">
    <name>University Hospital, Basel (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15761-1">
    <name>Cardiac Research Foundation, Basel (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-28T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-10-18T00:00:00.000Z">98820688</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of Hydrocortisone Treatment modality on Glycemic Control in patients with Septic Shock</title>
      <scientificTitle/>
      <acronym>HTGCSS</acronym>
      <studyHypothesis>Continuous hydrocortisone infusion will reduce the fluctuations in blood glucose levels in septic shock patients when compared to bolus treatment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mean blood glucose levels in study groups and the number of hyperglycemic (more than 7 mmol/l) and hypoglycemic (less than 3 mmol/l) episodes.</primaryOutcome>
      <secondaryOutcome>Shock reversal during the five day study period and the amount of nursing workload needed to maintain normoglycemia.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics commitee of Päijät-Häme Central Hospital, approval gained on 25th February 2005 (Code Q 71).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN98820688</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised prospective trial. Patients are randomised to receive hydrocortisone either by bolus or by continuous infusion in blocks of four patients. Study is not blinded nor placebo controlled.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d3af8922-4a06-4341-9f28-dc949462f82b">
	  <name>Kuopio University Hospital</name>
	  <address/>
	  <city>Kuopio</city>
	  <state/>
	  <country>Finland</country>
	  <zip>70211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Septic shock patients meeting the criteria for septic shock according to the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>48</totalTarget>
      <exclusion>1. Patients under 18 years of age
2. Patients with diabetes 
3. Patients receiving glucocorticoids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vasopressor-dependent septic shock</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Septic shock</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Septic shock patients who are considered to benefit from the corticosteroid treatment are randomly assigned to receive hydrocortisone either by bolus treament or by continuous infusion with equivalent dose (200 mg/day). During the study period a strict normoglycemic goal is maintained with continuous insulin infusion.  Duration of hydrocortisone treatment was five days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Hydrocortisone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17306016 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e5afb3c6-a5f9-452c-8211-0c7896675f98" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17306016"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15387-0</funderId>
      <funderId>Funder15387-1</funderId>
      <contactId>Contact53319_15387</contactId>
      <sponsorId>Sponsor51866</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53319_15387">
    <title>Dr</title>
    <forename>Esko</forename>
    <surname>Ruokonen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kuopio University Hospital
PO Box 1777</address>
      <city>Kuopio</city>
      <country>Finland</country>
      <zip>70211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51866">
    <organisation>Päijät-Häme Central Hospital (Finland)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+358 3 81911</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pekka.loisa@phks.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.440346.1</gridId>
    <rorId>https://ror.org/02v92t976</rorId>
  </sponsor>
  <funder id="Funder15387-0">
    <name>Medical Research Fund of Tampere University Hospital (Finland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15387-1">
    <name>Medical Research Fund of Päijät-Häme Central Hospital (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-10-16T00:00:00.000Z">87889245</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Circuit Weight Training to lower Blood Pressure in Obese individuals with Resistant Hypertension</title>
      <scientificTitle/>
      <acronym>CT, ORH &amp; BP</acronym>
      <studyHypothesis>In comparison with the Usual Care group (UC), obese hypertensive individuals undergoing 12 weeks of Circuit Weight Training (CWT), will exhibit greater reductions in blood pressure.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Efficacy of prescribing circuit weight training in reducing blood pressure of obese resistant hypertensives</primaryOutcome>
      <secondaryOutcome>1. Effiacy of circuit weight training in reducing weight
2. Increasing cardio-respiratory endurance
3. Improving glycemic control and lipid profiles 
4. Enhancing Health Related Quality of Life (HRQL)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>University of Alberta Health Research Ethics Board (HREB) (ref no: 6276).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87889245</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RF-06-0419</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>This study has been cancelled due to the private fitness centre pulling out of the trial.</reasonAbandoned>
      <overallStartDate>2006-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="af1cc191-7497-485f-8b7a-5662bc1d5ca9">
	  <name>Clinical Pharmacology and Internal Medicine</name>
	  <address/>
	  <city>Alberta</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T6G 2B7</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 25 to 70 years
2. Obese (Body Mass Index [BMI] more than 30 kg/m^2)
3. Mean 24 hour ambulatory blood pressure of 150/99 mmHg or less (on drug therapy)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40 (20 randomised into either group)</totalTarget>
      <exclusion>1. White-coat hypertension
2. Secondary hypertension
3. Unstable cardiovascular disease
4. Not residing in Edmonton or the surrounding area</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Obesity and /or resistant hypertension</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Circuit Weight Training (CWT) group: Individuals will be prescribed an exercise regimen based on baseline fitness and strength assessments and their exercise blood pressure response. Loads prescribed will be low resistance but high volume (two to three sets of 15 repetitions). Subjects will be asked to train on at least three non-consecutive days of the week and given free membership to local health club facilities for the duration of the intervention (12 weeks). Adherence to CWT intervention will be monitored via electronic attendance records at the health club facilities

Usual Care (UC) Group: Individuals randomly assigned to the usual care group will be asked to continue their current level of activity for the duration of the intervention (12 weeks).

Both groups will recieve the same nutritional counselling at the start of the intervention.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15075-0</funderId>
      <contactId>Contact52912_15075</contactId>
      <sponsorId>Sponsor51462</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52912_15075">
    <title>Dr</title>
    <forename>Raj</forename>
    <surname>Padwal</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical Pharmacology and Internal Medicine
University of Alberta 
2E3.22 Walter C. Mackenzie Health Sciences Center
8440 - 112 Street
Edmonton</address>
      <city>Alberta</city>
      <country>Canada</country>
      <zip>T6G 2B7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 780 407 8153</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rpadwal@ualberta.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51462">
    <organisation>University of Alberta (Canada)</organisation>
    <website>http://www.ualberta.ca</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>114 St - 89 Avenue
Edmonton</address>
      <city>Alberta</city>
      <country>Canada</country>
      <zip>T6G 2E1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.17089.37</gridId>
    <rorId>https://ror.org/0160cpw27</rorId>
  </sponsor>
  <funder id="Funder15075-0">
    <name>University of Alberta Hospital Foundation (Canada) (ref: RF-06-0419)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-06T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-09-29T00:00:00.000Z">14811769</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A clinical comparison of self-etching primer with conventional etch during fixed appliance treatment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does self etching primer provide satisfactory clinical performance with similar failure rates compared to conventional etch?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Percentage bond failure rate.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14811769</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0155160660</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8fe58a4c-788f-4b7b-b6f6-f7ac7f82a4e5">
	  <name>Dept of Oral and Maxollofacial Surgery</name>
	  <address/>
	  <city>Bury</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BL9 7TD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients requiring fixed appliance treatment.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Patients who require bands or have heavily restored teeth.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Oral Health</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomised controlled trial: self-etching primer compared to conventional etch.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/18042825 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e4978f90-3539-449c-b9bb-e97148a52403" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/18042825"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15527-0</funderId>
      <funderId>Funder15527-1</funderId>
      <contactId>Contact53460_15527</contactId>
      <sponsorId>Sponsor52007</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53460_15527">
    <title>Mr</title>
    <forename>PA</forename>
    <surname>BANKS</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept of Oral and Maxollofacial Surgery
Fairfield General Hospital
Rochdale Old Road</address>
      <city>Bury</city>
      <country>United Kingdom</country>
      <zip>BL9 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52007">
    <organisation>Record Provided by the NHSTCT Register - 2006 Update - Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health, Richmond House, 79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15527-0">
    <name>Pennine Acute Hospitals NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15527-1">
    <name>NHS R&amp;D Support Funding (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-02-17T00:00:00.000Z">18723747</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Influence of ibuprofen-arginine on serum levels of nitric oxide metabolites in patients with chronic lower back pain: a single-blind, placebo-controlled pilot trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The present study investigates whether ibuprofen-arginine has a cyclooxygenase-independent pain modulating property besides its known anti-inflammatory effect.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>No metabolites.</primaryOutcome>
      <secondaryOutcome>Pain intensity (VAS).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics committee (Kantonale Ethics commission Zurich) on the 8th November 2002 (ref: 427).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18723747</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2003DR4004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A single-blind, placebo-controlled pilot trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-03-04T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-10-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="244eea26-6ebb-438e-9e9c-4ad64620ef94">
	  <name>Department of Rheumatology</name>
	  <address/>
	  <city>Zurich</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-8091</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Non-specific chronic lower back pain (Visual Analogue Scale [VAS] greater than or equal to 60).</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Specific lower back pain.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-03-04T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-10-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lower back pain</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Lower back pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Ibuprofen-arginine 400 mg (verum) was administered orally once.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ibuprofen-arginine 400 mg (verum)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/17013995 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1f3089cf-2288-41bb-8407-b8b4e77cfcae" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17013995"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14814-0</funderId>
      <contactId>Contact52586_14814</contactId>
      <sponsorId>Sponsor51111</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52586_14814">
    <title>Dr</title>
    <forename>Haiko</forename>
    <surname>Sprott</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Rheumatology
Institute of Medical Research
University Hospital of Zurich
Gloriastrasse 25</address>
      <city>Zurich</city>
      <country>Switzerland</country>
      <zip>CH-8091</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)44 255 3010</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">haiko.sprott@usz.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51111">
    <organisation>Zambon Svizzera S.A. (Switzerland)</organisation>
    <website>http://www.inpharzam.ch/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Via Industria 13
Casella postale 200</address>
      <city>Cadempino</city>
      <country>Switzerland</country>
      <zip>CH-6814</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)91 960 4118</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Ralf.Ruffmann@zambongroup.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487420.d</gridId>
    <rorId>https://ror.org/04zrd1t35</rorId>
  </sponsor>
  <funder id="Funder14814-0">
    <name>Zambon Svizzera S.A. (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-04T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">52543592</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of transfusions with platelets stored in platelet additive solution II versus plasma</title>
      <scientificTitle>A multicenter randomised study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma</scientificTitle>
      <acronym/>
      <studyHypothesis>Utilisation of platelets stored in additive solutions has several advantages. A former Randomised Controlled Trial (RCT) testing platelets stored in platelet additive solution II versus plasma excluded patients with factors of increased platelet consumption. In this study also this category of patients are included and we expect to find differences in outcome, as compared to the previous study.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1- and 24-hour corrected count increment.</primaryOutcome>
      <secondaryOutcome>1. Bleeding complications
2. Transfusion reactions
3. Transfusion interval</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol was approved by the Leiden University Medical Center and HagaZiekenhuis ethics committees and conducted according to the Guidelines of Good Clinical Practice.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52543592</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P03.113</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, double blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="def5a331-7199-4947-8d61-0992295f2d3c">
	  <name>Leyenburg Hospital,</name>
	  <address/>
	  <city>Den Haag</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2504 LN</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients greater than 18 years expected to receive platelet transfusions.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>195</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>195</totalTarget>
      <exclusion>HLA- and/or HPA allo-immunisation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Platelet transfusion</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Transfusion</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Platelet transfusion, trigger based.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16825492 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="be13d427-03d4-43cc-8d4e-2c8868e51f71" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16825492"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14500-0</funderId>
      <contactId>Contact52162_14500</contactId>
      <sponsorId>Sponsor50712</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52162_14500">
    <title>Dr</title>
    <forename>J.L.H</forename>
    <surname>Kerkhoffs</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leyenburg Hospital,
Department of Hematology,
P.O. Box 40551</address>
      <city>Den Haag</city>
      <country>Netherlands</country>
      <zip>2504 LN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">JeanLouis.Kerkhoffs@bloodrtd.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50712">
    <organisation>Leyenburg Hospital (The Netherlands) - Department of Hematology</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 40551</address>
      <city>Den Haag</city>
      <country>Netherlands</country>
      <zip>2504 LN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413591.b</gridId>
    <rorId>https://ror.org/03q4p1y48</rorId>
  </sponsor>
  <funder id="Funder14500-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">48093674</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Transfusion induced complications = transfusion associated complications? study</title>
      <scientificTitle>The effects of leukocyte filtered versus buffy coat depleted erythocyte transfusions in major surgery patients</scientificTitle>
      <acronym>TACTICS</acronym>
      <studyHypothesis>Does removal of allogeneic white blood cells by filtration reduce postoperative complications?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Postoperative:
1. In-hospital mortality
2. Duration of intensive care stay</primaryOutcome>
      <secondaryOutcome>1. Postoperative multi organ failure
2. Postoperative infections
3. Length of hospital stay
4. Costs/benefits of universal leukocyte depletion for the Dutch health care
5. Role of perioperative medication

Follow up :
1. Long term survival
2. Cancer recurrence in GI patients
3. Predictive role of cytokines and related genes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48093674</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>n/a</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, double blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0d866563-6d00-4802-9cfc-a065aee450f6">
	  <name>Sanquin Blood Supply Foundation</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2310 CD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Acute aneurysm-, elective aneurysm-, orthopaedic- and large gastro-intestinal surgery patients.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1548</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1548</totalTarget>
      <exclusion>1. Under 18 years of age
2. Transfusions received within 3 months prior to inclusion
3. Pre existing medical indication for filtered red blood cell transfusions</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Blood transfusions complications</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Blood transfusions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Transfusions of filtered red blood cell concentrates versus transfusion of stored buffy coat depleted red blood cell concentrates.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15142885 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5c1e9b42-ce5c-478d-bd72-7f4d3ee43b53" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-05-29T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15142885"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14510-0</funderId>
      <funderId>Funder14510-1</funderId>
      <contactId>Contact52156_14510</contactId>
      <sponsorId>Sponsor50754</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52156_14510">
    <title>Dr</title>
    <forename>J.A.</forename>
    <surname>Hilten, van</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sanquin Blood Supply Foundation
P.O. Box 2184</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2310 CD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 5685060</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Joost.vanhilten@bloodrtd.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50754">
    <organisation>Leiden University Medical Centre (LUMC) (Netherlands)</organisation>
    <website>http://www.lumc.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Albinusdreef 2
P.O. Box 9600</address>
      <city>Leiden</city>
      <state/>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder14510-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14510-1">
    <name>Sanquin Bloodbank Amsterdam (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-10T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2005-11-16T00:00:00.000Z">26422175</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A clinical trial of the effectiveness of a dental caries prevention program for young children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The hypotheses are that at study completion: 
1. Children of caregivers randomised to the intervention group will have a mean number of decayed, missing or filled tooth surfaces (dmfs) one less than that of children whose caregivers were randomised to the control group
2. The proportion of children of caregivers in the intervention group who are caries free will be 20% more than the proportion of children caries free in the control group</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of decayed missing and filled tooth surfaces 24 months following recruitment.</primaryOutcome>
      <secondaryOutcome>1. Percentage of children without dental caries
2. Parent caries-related knowledge
3. Parent caries-related behaviour
4. Oral health-related impacts/quality of life
5. Child weight
6. Financial costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the McGill Faculty of Medicine Institutional Review Board on the 6th January 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26422175</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-63155</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="712eae6a-155b-4220-be70-eaf75cfd60ff">
	  <name>Faculty of Dentistry</name>
	  <address/>
	  <city>Montreal</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H3A 2B2</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Caregivers (parents) who have a child of five to seven months, either sex (inclusive), with whom they are attending the vaccination clinics of the study community health centre recruitment sites (CLSCs) and who live with that child for 50% or more of the time will be asked to participate
2. The subjects included are parent/infant dyads</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="5.0"/>
      <upperAgeLimit unit="Months" value="7.0"/>
      <gender>Both</gender>
      <targetEnrolment>821</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>821</totalTarget>
      <exclusion>Dyads will be excluded if parents are unable to understand the consent form and self-complete questionnaires for linguistic reasons</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Early childhood caries</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The test intervention is an educational one delivered by dental hygienists to parents of infants when the latter are 6, 12, 18 and 24 months old. Each of the four sessions lasts approximately 15 minutes.

The control group receive no intervention i.e. 'normal care'.

Trial details received: 12 September 2005</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14206-0</funderId>
      <contactId>Contact51921_14206</contactId>
      <sponsorId>Sponsor50352</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51921_14206">
    <title>Dr</title>
    <forename>Paul John</forename>
    <surname>Allison</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Faculty of Dentistry
McGill University
Rm 238D, Strathcona Building
3640, University St.</address>
      <city>Montreal</city>
      <country>Canada</country>
      <zip>H3A 2B2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 398 7203 (00045)</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">paul.allison@mcgill.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50352">
    <organisation>McGill University (Canada)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>3640 University St.</address>
      <city>Montreal</city>
      <country>Canada</country>
      <zip>H3A 2B2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.14709.3b</gridId>
    <rorId>https://ror.org/01pxwe438</rorId>
  </sponsor>
  <funder id="Funder14206-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-63155)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-11-16T00:00:00.000Z">26202234</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of the effectiveness of a coping strategies intervention for people with head and neck cancer</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Psychological distress in people with head and neck cancer. Those receiving the test intervention will have reduced psychological distress compared to those in the control group. 

To test the effectiveness of the test intervention in reducing symptoms of psychological distress in people with head and neck cancer.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Psychological distress symptoms as indicated by the depression scale of the Hospital Anxiety and Depression Scale (HADS) at 4 months following randomisation.</primaryOutcome>
      <secondaryOutcome>1. Mean HADS anxiety and depression scale scores (measured at 8 weeks, 4, 8 months)
2. Quality of life, measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) Core 30 and Head and Neck (H&amp;N35) module
3. Coping strategies (measured using the Ways of Coping Checklist) 
4. Smoking and alcohol consumption behaviours
5. 2 year post-diagnosis survival
6. Recurrent head and neck cancer incidence
7. New head and neck cancer incidence 
8. Cost per depression averted</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of McGill University, Montreal, Canada on the 25 July 2005.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26202234</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-75475</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e1a11ff7-a6f1-4c18-b8ac-52af7b871fd6">
	  <name>Faculty of Dentistry</name>
	  <address/>
	  <city>Montreal</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H3A 2B2</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Are diagnosed with a primary cancer of the head and neck region (International Statistical Classification of Diseases and Related Health Problems [ICD-9] 140-149 and 161; lip, salivary glands, tongue, floor of mouth, other mouth, oropharynx, nasopharynx, other pharynx and larynx)
2. Age 18 years and older, either sex
3. Were diagnosed 6 - 12 months previously
4. Scored greater than 7 on one or both of the anxiety and depression scales of the Hospital Anxiety and Depression Scale (HADS)
5. Are able to understand and complete either English or French language questionnaires
6. Have signed a consent form</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>1. Are undergoing palliative or terminal care only
2. Have a previous history of malignant disease affecting other parts of their body
3. Have been diagnosed with depression and are currently undergoing any anti-depressive therapy
4. Live beyond 90 minutes traveling time by car/taxi from the site where they are recruited AND are unable or unwilling to travel to the recruitment hospital to receive the intervention as an alternative. This exclusion criterion will be used because a small proportion of patients at these clinics travel considerable distances for treatment and a limit must be made concerning the traveling time necessary for the therapists in the study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Head and neck cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Head and neck</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The test intervention is the 'Nucare program'; a psycho-educational intervention designed to teach cancer patients strategies to help them cope with having their disease. The intervention is a structured training package, delivered by trained therapists during 2-3 one-two hour sessions.
The control intervention is an attention placebo in which individuals are invited to talk with the therapists concerning any problems they have with their cancer and treatment.

Trial details received 12 Sept 2005</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14204-0</funderId>
      <contactId>Contact51920_14204</contactId>
      <sponsorId>Sponsor50352</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51920_14204">
    <title>Dr</title>
    <forename>Paul John</forename>
    <surname>Allison</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Faculty of Dentistry
McGill University
Rm 238D
Strathcona Building
3640, University St.</address>
      <city>Montreal</city>
      <country>Canada</country>
      <zip>H3A 2B2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 398 7203 (00045)</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">paul.allison@mcgill.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50352">
    <organisation>McGill University (Canada)</organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>3640 University St.</address>
      <city>Montreal</city>
      <country>Canada</country>
      <zip>H3A 2B2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.14709.3b</gridId>
    <rorId>https://ror.org/01pxwe438</rorId>
  </sponsor>
  <funder id="Funder14204-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-75475)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-11-08T00:00:00.000Z">04750658</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised open multicentre trial comparing stavudine versus abacavir, both combined with lamivudine/efavirenz, in Human Immunodeficiency Virus (HIV) infected antiretroviral naïve patients</title>
      <scientificTitle/>
      <acronym>ABCDE study</acronym>
      <studyHypothesis>To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of patients with lipoatrophy as assessed by physician and patient observation at 96 weeks.</primaryOutcome>
      <secondaryOutcome>1. Virological, clinical and immunological efficacy
2. Tolerability</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN04750658</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ARV/01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised open multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e736f2b4-db25-49d1-a20c-61c9caac92d9">
	  <name>Infectious Disease Service</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08907</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. HIV positive confirmed by Western blot
2. Adult 18 - 70 years
3. No previous antiretroviral therapy
4. HIV-1 Ribonucleic Acid (RNA) greater than 1500 copies/ml (Polymerase Chain Reaction [PCR], Nucleic Acid Sequence Based Amplification [NASBA] or branched-chain Deoxyribonucleic Acid [bDNA]) within 12 weeks prior to study initiation
5. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>232</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>232 patients (116 per arm)</totalTarget>
      <exclusion>1. Prior antiretroviral therapy
2. Concomitant participation in another clinical trial
3. Signs of hepatic cirrhosis
4. Any of the following laboratory parameter alterations: 
4.1. Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than 5 times above the normal values
4.2. Creatinine clearance less than 50 ml/min
4.3. Amylases greater than 3 times above normal values
4.4. Hemoglobin less than 8 mg/dl
4.5. Neutrophils less than 500/µl
4.6. Platelets less than 30,000/µl
5. Pregnancy
6. Contraindicated drugs
7. Active infection within the last 4 weeks
8. Treatment for neoplasms</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Human immunodeficiency virus (HIV) infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human immunodeficiency virus (HIV)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will centrally be stratified according to HIV-1 RNA greater than or less than or equal to 30,000 copies/ml and CD4 counts greater than or less than or equal to 200 cells/µl; and randomised to one of these arms:
1. Abacavir 300 mg twice a day (bid), plus lamivudine 150 mg bid, plus efavirenz 600 mg once a day (qd)
2. Stavudine 30 - 40 mg bid (according to less than or more than 60 kg body weight) plus lamivudine and efavirenz at the same doses as group 1</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Stavudine, abacavir</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17106274 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="839bb869-56aa-4276-ab96-c8197a6ee705" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17106274"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14154-0</funderId>
      <contactId>Contact51849_14154</contactId>
      <sponsorId>Sponsor50273</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51849_14154">
    <title>Dr</title>
    <forename>Daniel</forename>
    <surname>Podzamczer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Infectious Disease Service
Hospital Universitari de Bellvitge
c/Feixa Llarga s/n
L'Hospitalet</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dpodzamczer@csub.scs.es</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50273">
    <organisation>Network of Research on AIDS (Red de Investigacion en SIDA [RIS]) (Spain)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>IDIBAPS
c/Villarroel 170</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08036</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder14154-0">
    <name>Network of Research on AIDS (Red de Investigacion en SIDA [RIS]) (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-10-31T00:00:00.000Z">16784092</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised placebo-controlled pilot trial of granulocyte-colony stimulating factor in mobilising bone marrow stem cells in sub-acute stroke: the 'Stem cell Trial of recovery EnhanceMent after Stroke' (STEMS) pilot study</title>
      <scientificTitle/>
      <acronym>STEMS</acronym>
      <studyHypothesis>Loss of motor function is common after stroke and often leads to significant long-term disability. Stem cells can be mobilised into the circulation using granulocyte-colony stimulating factor (G-CSF), an approach that has been found to be effective in experimental stroke. We aim to perform a pilot randomised placebo-controlled dose-escalation trial of G-CSF (1 x 10^5 - 3 x 10^6 µ/kg given once or once daily for 5 days, in dosing blocks: 1 dose or 5 doses 1 x 10^5 µkg - 3 x 10^6 µ/kg, with level of 5 dose blocks depending on single dose data) in patients with motor weakness following ischaemic stroke, investigating its safety, feasibility of administration, tolerability, and effects on stem cell mobilisation, impairment, disability and dependency. The interaction between G-CSF and routine rehabilitation will be examined. 

The study will last 24 months with 42 patients recruited over 19 months allowing 3 months follow-up. The results will help inform the design (inclusion criteria, outcomes, size) of further trials including the planning of a large definitive trial assessing the safety and efficacy (motor recovery and functional outcome) of G-CSF.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Circulating CD 34+ (flow cytometry) stem cells - aim greater than 10 x 10^6/l
2. Clinical safety: death, recurrent stroke, deterioration, palpable splenomegaly, at 10 days
3. Laboratory safety: white cell count (WCC, differential), platelet count (PC)</primaryOutcome>
      <secondaryOutcome>Clinical efficacy: 
1. Impairment (SSS)
2. Disability (Barthel Index, [BI])
3. Dependency (mRS)
4. Cognition (Mini Mental State Examination [MMSE])
5. Depression (Zung)
6. Quality of life (EuroQOL)
7. Disposition (home, institution) 

Outcomes measurd at 10 and 90 days.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Nottingham Local Research Committee on the 5th June 2003 and had Medicines and Healthcare Products Regulatory Agency Clinical Trial Authorisation on the 10th March 2003).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16784092</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Version  1.3  28/06/04</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised placebo controlled pilot trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d5fb5807-090f-4a76-ac5e-e1a3398e5a0c">
	  <name>University of Nottingham</name>
	  <address/>
	  <city>Nottingham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>NG5 1PB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinical stroke (lacunar or cortical)
2. 7 - 30 days post-onset
3. Arm and/or leg weakness (Scandinavian Stroke Scale [SSS], arm and/or leg motor power less than 6)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>42</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>42</totalTarget>
      <exclusion>1. Pre-morbid dependency, modified Rankin scale (mRS) greater than 3
2. Primary intracerebral haemorrhage
3. Dementia
4. Coma (SSS consciousness less than 4)
5. Malignancy
6. Sickle cell disease
7. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Stroke (ischaemic)</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Stroke</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subcutaneous human recombinant G-CSF (filgrastim from Amgen) versus placebo.
G-CSF - 1 x 10^5 - 3 x 10^6 µ/kg given once or once daily for 5 days, in dosing blocks: 1 dose or 5 doses 1 x 10^5 µ/kg - 3 x 10^6 µ/kg, with level of 5 dose blocks depending on single dose data.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/17082474 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="cb8aafc8-bc27-4237-9cec-1c7c517b389e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17082474"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13426-0</funderId>
      <contactId>Contact51065_13426</contactId>
      <sponsorId>Sponsor49462</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51065_13426">
    <title>Prof</title>
    <forename>Philip</forename>
    <surname>Bath</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Nottingham
Clinical Sciences Building
Nottingham City Hospital Campus</address>
      <city>Nottingham</city>
      <country>United Kingdom</country>
      <zip>NG5 1PB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49462">
    <organisation>University of Nottingham (UK)</organisation>
    <website>http://www.nottingham.ac.uk</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Clinical Sciences Building
Nottingham City Hospital Campus</address>
      <city>Nottingham</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>NG5 1PB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4563.4</gridId>
    <rorId>https://ror.org/01ee9ar58</rorId>
  </sponsor>
  <funder id="Funder13426-0">
    <name>The Stroke Association (UK) (ref: TSA 01/03)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-10-27T00:00:00.000Z">78563659</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study to investigate the effect of pioglitazone on whole body and myocardial glucose uptake and myocardial blood flow/coronary vasodilator reserve in patients with familial combined hyperlipidaemia</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The disturbance of fat metabolism (utilisation) known as combined hyperlipidaemia (CHL) is very common and affects up to 2% of the population. Patients who suffer from this disorder have a 20% higher risk to develop obstructive disease of the blood vessels of the heart and heart attack.

The patients with CHL have abnormalities of blood lipids (fat) similar to those observed in patients who suffer from another condition known as the 'metabolic syndrome' who are also at higher risk of developing heart disease, stroke and diabetes. One of the features of this metabolic syndrome is a reduced response to the hormone insulin. This hormone helps the tissues of the body (in particular the muscles and the heart) to use sugar. Sugar is very important for the heart since it contributes to generate the energy which is used to sustain its function.

In patients with the metabolic syndrome insulin is less effective and the heart tissue has difficulties in using sugar and develops a condition known as 'insulin resistance'. Previous studies have shown that this condition of insulin resitance can contribute to the higher incidence of heart disease in patients with the metabolic syndrome.

Pioglitazone is a drug licenced in the UK which acts by sensitising the liver and peripheral tissues (including the heart) to the effect of insulin, which results in improved insulin-mediated sugar disposal. Previous studies have demonstrated that pioglitazone lowers sugar and insulin levels in the blood and improves lipid (fat) metabolism (utilisation) in patients with diabetes. We expect similar beneficial effects in patients with familial CHL treated with pioglitazone.

We therefore hypothesise that patients with CHL will have insulin resistance at the heart muscle level as well as an abnormal function of the vessels supplying blood to the heart and that treatment with pioglitazone will improve these

To prove our hypothesis we will use a special scan called Positron Emission Tomography (PET) which permits to measure the utilisation of sugar by the heart in a totally non-invasive fashion. PET is also capable of providing information on the function of the vessels supplying blood to the heart. Patients with familial CHL will be studied by means of PET before and after 4 months of treatment with pioglitazone. In addition, we will assess the effect of the drug on blood lipids (fat).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Whole body glucose uptake
2. Myocardial glucose uptake
3. Basal myocardial blood flow
4. Coronary vasodilator reserve</primaryOutcome>
      <secondaryOutcome>Parameters of lipid and carbohydrate metabolism.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Hammersmith &amp; Queen Charlotte's and Chelsea Hospitals Research Ethics Committee (ref: 2002/6373).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN78563659</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>AD-4833 / EC414</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-19T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1e8f586b-d1e1-444a-b1d5-362f5b79f3fe">
	  <name>MRC Clinical Sciences Centre</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>W12 0NN</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients must be/have:
1. Male or female aged between 30 and 70 years
2. Familial Combined Hyperlipidaemia (CHL) that fits the diagnostic criteria
3. Inadequately controlled with conventional lipid lowering medication, with at least one of
the following:
3.1. Total cholesterol more than 5.0 mmol/l
3.2. Triglyceride more than 1.7 mmol/l
3.3. High Density Lipoprotein (HDL) cholesterol less than 1.0 mmol/l
3.4. Total cholesterol: HDL-cholesterol ratio more than 5.0
4. On stable lipid lowering medication (dose and drug) for the previous two months
5. A Body Mass Index (BMI) of less than or equal to 35 kg/m^2
6. Willing and able to comply with the conditions and requirements of the study
7. Signed and dated an informed consent form and be able to comply with the study procedures</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>26</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>26</totalTarget>
      <exclusion>Patients must not be/have:
1. Had a myocardial infarction, stroke or transient ischaemic attack in the previous six months
2. Had malignant disease in the previous five years (except basal cell carcinoma)
3. Undergoing haemodialysis
4. Any of the following conditions:
4.1. Type one or type two diabetes mellitus
4.2. Chronic uncontrolled asthma
4.3. An inability to tolerate PET scanning
4.4. New York Heart Association (NYHA) class II, III or IV congestive heart failure
4.5. Alcohol or drug abuse
4.6. Significant renal impairment (defined as creatinine more than 135 µmol/l)
4.7. Abnormal liver tests (defined as alanine aminotransferase [ALT] more than 2.5 times the upper limit of the reference range)
4.8. Known Human Immunodeficiency Virus (HIV) infection or viral hepatitis
5. Had treatment with corticosteroids in the previous four weeks (use of topical or inhaled corticosteroids is allowed)
6. Taken another investigational study drug or product within the previous three months
7. Donated and/or received any blood or blood products within the previous three months
8. Female patients who are any of the following:
8.1. Pregnant, planning pregnancy during the study or breast feeding
8.2. Of child-bearing potential and not planning to use a reliable method of contraception throughout the study (e.g. intrauterine device [IUD] or oral contraception)
9. Any other condition or circumstance that in the opinion of the investigator may compromise the patient&#146;s ability to comply with the study protocol</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-19T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Familial Combined Hyperlipidaemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Hyperlipidaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment with pioglitazone versus placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pioglitazone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/18021872 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f2e984bf-73bd-468e-b864-fb61e978eab7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/18021872"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13576-0</funderId>
      <contactId>Contact51241_13576</contactId>
      <sponsorId>Sponsor49641</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51241_13576">
    <title>Prof</title>
    <forename>Paolo</forename>
    <surname>Camici</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>MRC Clinical Sciences Centre
Hammersmith Hospital
Du Cane Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W12 0NN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49641">
    <organisation>Takeda Europe R and D Centre (UK)</organisation>
    <website>http://www.tgrd.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Savannah House
11-12 Charles II Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1Y 4QU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.451362.7</gridId>
    <rorId>https://ror.org/05c0v3585</rorId>
  </sponsor>
  <funder id="Funder13576-0">
    <name>Takeda Europe R and D Centre (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-10T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-09-26T00:00:00.000Z">97731480</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Optimal perioperative analgesia in hand surgery</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare two methods of analgesia, optimal perioperative analgesia OPA versus the usual analgesic treatment (UAT), in patients undergoing hand surgery, in terms of postoperative pain control, intensity and duration of the local inflammatory response, impact of pain on function and quality of life.

Trapeziectomy and carpal surgery, bone graph, wrist arthrodesis, distal radial arthrotomy, hand surgery/trauma of hand.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Reducing pain intensity at rest and during active movements measured at 8 months.</primaryOutcome>
      <secondaryOutcome>1. The impact of pain on Quality of Life (QOL)
2. The impact of pain on activities
3. Inflammation
4. Function</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Comité d'éthique de la recherche, CHUM (Centre Hospitalier de l'Université de Montréal) on the 24th March 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97731480</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-65009</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="92cdc812-4ace-4899-9b13-c6e9353caac4">
	  <name>Hôpital Notre-Dame du CHUM</name>
	  <address/>
	  <city>Montréal</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H2L 4M1</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients, either sex, scheduled for trapeziectomy and carpal surgery:
1. Total and partial carpectomy
2. Bone graph
3. Wrist arthrodesis
4. Distal radial arthrotomy</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>220</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>220</totalTarget>
      <exclusion>1. Age under 18 years or older than 75 years
2. Pregnant
3. Allergic to morphine, local anesthetics
4. Suffering from other forms of chronic arthritis or other painful conditions treated chronically (every day) with analgesics (i.e. fibromyalagia)
5. Allergic or intolerant to NSAID (COX2 inhibitors)
6. Consuming anticoagulants which cannot be interrupted
7. Suffering from major cardiovascular problems
8. Suffering from cognitive or psychiatric problems, or drug abuse
9. Other recent hand surgery or axillary surgery with sequels
10. Living alone (no help at home)
11. Unable to understand French or English
12. Without phone access or likely to change address during follow-up</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hand surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Hand surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Experimental group: non-steroidal anti-inflammatory drug (NSAID) 1 hour before surgery, 1 daily after surgery.
Both groups (OPA and UAT) will receive the same treatment until their admission in the recovery room.

Trial details received: 12 September 2005</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Non-Steroidal Anti-Inflammatory Drugs (NSAID)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13770-0</funderId>
      <contactId>Contact51467_13770</contactId>
      <sponsorId>Sponsor49866</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51467_13770">
    <title>Dr</title>
    <forename>Gilbert Alfred</forename>
    <surname>Blaise</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hôpital Notre-Dame du CHUM
Laboratoire d'Anesthésie
Porte FS-1136
1560 rue Sherbrooke Est</address>
      <city>Montréal</city>
      <country>Canada</country>
      <zip>H2L 4M1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514-890-8202</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">blaisegil@sympatico.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49866">
    <organisation>University Hospital of Montreal (CHUM) (Canada)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Campus Hôtel-Dieu
3840 rue Saint-Urbain</address>
      <city>Montréal</city>
      <country>Canada</country>
      <zip>H2W 4M1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410559.c</gridId>
    <rorId>https://ror.org/0410a8y51</rorId>
  </sponsor>
  <funder id="Funder13770-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-65009)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-11T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-26T00:00:00.000Z">64506738</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of NMDA-receptor antagonism on hyperalgesia, opioid use, and pain after major surgery in young and elderly patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Our primary aim is to determine whether perioperative NMDA-receptor antagonism has differential effects on postoperative pain, hyperalgesia and morbidity in younger and older patients. In order to achieve this aim, we propose to conduct the first randomized, double-blind placebo-controlled study designed to investigate age differences in the effects of perioperative oral administration of an NMDA-receptor antagonist (amantadine) in men undergoing radical prostatectomy. In addition, age differences in psychosocial factors and the pharmacological properties of amantadine and morphine will be measured to control for, and clarify, their contribution to the differences found.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Hyperalgesia and opioid consumption.</primaryOutcome>
      <secondaryOutcome>Assess age differences in the intensity and course of secondary hyperalgesia after surgery.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the University Health Network Research Ethics Board, Toronto, Ontario on the 12th November 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64506738</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-52682</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fed3fa8b-2166-4c45-895f-0e6a8bfc9b1c">
	  <name>Department of Anaesthesia</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M5G 2C4</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Able to read and write English
2. Age 18 - 54 years or greater than 55 years, male
3. American Society of Anesthesiologists (ASA) class 1 to 3
4. Scheduled for elective radical prostatectomy
5. Body weight between 60 and 90 kg, Body Mass Index (BMI) less than or equal to 30</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Male</gender>
      <targetEnrolment>132</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>132</totalTarget>
      <exclusion>1. Significant Central Nervous System (CNS), respiratory, cardiac, hepatic, renal or endocrine dysfunction and/or any significant sequelae
2. Contraindications allergies to, and/or past adverse reactions to opioid analgesics or amantadine
3. History of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) axis I disorder or cognitive dysfunction
4. History of epilepsy or other seizures
5. History of chronic pain of at least 6 months duration
6. History of long-term opioid use for chronic pain
7. History of long-term use of amantadine or other antiparkinsonian drug
8. Ingestion of antiussive medication within 48 hours before surgery
9. History of alcohol or drug dependency/abuse of at least 6 months duration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Postoperative pain in radical prostatectomy</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Postoperative pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Amantadine versus Placebo comparison.

Trial details received: 12 September 2005</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Amantadine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13777-0</funderId>
      <contactId>Contact51474_13777</contactId>
      <sponsorId>Sponsor49873</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51474_13777">
    <title>Dr</title>
    <forename>Lucia</forename>
    <surname>Gagliese</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Anaesthesia
Toronto General Hospital
200 Elizabeth Street</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 2C4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 340 4296</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lucia.gagliese@uhn.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49873">
    <organisation>University Health Network, Toronto (Canada)</organisation>
    <website>http://www.uhnresearch.ca </website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>200 Elizabeth Street</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 2C4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kfibiger@uhnres.utoronto.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.417184.f</gridId>
    <rorId>https://ror.org/026pg9j08</rorId>
  </sponsor>
  <funder id="Funder13777-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-52682)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-15T00:00:00.000Z">00079388</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Routine Screening in the management of Abdominal Aortic Aneurysms (AAA)</title>
      <scientificTitle/>
      <acronym>Management of AAA</acronym>
      <studyHypothesis>To establish prevalence and incidence of AAA in the community. Study effect of screening on mortality from ruptured AAA and on surgical workload and NHS costs.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Prevalence and incidence of AAA in men and women 65 - 80 years of age in community.</primaryOutcome>
      <secondaryOutcome>The effect of AAA screening on mortality from AAA and AAA surgical workload.</secondaryOutcome>
      <trialWebsite>http://www.scottunit.org</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN00079388</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>121/2133 and PA1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1989-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2015-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6c57a391-8c54-47d8-af79-8438d55083ef">
	  <name>Scott Research Unit</name>
	  <address/>
	  <city>Chichester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>PO19 6SE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men and women aged 65 - 80 years</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>16000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>16,000</totalTarget>
      <exclusion>No specific exclusions</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1989-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2015-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Abdominal Aortic Aneurysms (AAA)</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Screening for abdominal aortic aneurysm (AAA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>50% randomised to ultrasound screening. Surveillance of patients with detected AAA. All subjects considered for surgical AAA repair if clinical need.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17514666 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="350b2210-4340-454f-87ca-6043f7bbea88" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17514666"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13405-0</funderId>
      <funderId>Funder13405-1</funderId>
      <funderId>Funder13405-2</funderId>
      <contactId>Contact51042_13405</contactId>
      <sponsorId>Sponsor49435</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51042_13405">
    <title>Mr</title>
    <forename>R Alan P</forename>
    <surname>Scott</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Scott Research Unit
CMEC
St Richard's Hospital</address>
      <city>Chichester</city>
      <country>United Kingdom</country>
      <zip>PO19 6SE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1243 831503</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">scottunit@rws-tr.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49435">
    <organisation>Department of Health (UK)</organisation>
    <website>http://www.dh.gov.uk/en/index.htm</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House 
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)151 794 5900</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dot.lambert@dh.gsi.gov.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.57981.32</gridId>
    <rorId>https://ror.org/03sbpja79</rorId>
  </sponsor>
  <funder id="Funder13405-0">
    <name>Department of Health (UK): 1989 - 1993 (ref: 121/2133)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13405-1">
    <name>DOH NHS R&amp;D Programme for Cardiovascular Disease and Stroke (UK): 1994 - 1999 (ref: PA1)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13405-2">
    <name>Charitable donations and 'own account funding' (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-09-14T00:00:00.000Z">18622460</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of an intervention to treat and prevent depression in older people following hip fracture</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>An intervention will reduce the incidence of depression and improve the symptoms of depression following hip fracture.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Rates of depression.</primaryOutcome>
      <secondaryOutcome>Functional outcome.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18622460</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cf5c58c6-95bc-45b6-a43c-af41c2e5192c">
	  <name>Wythenshawe Hospital</name>
	  <address/>
	  <city>Manchester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>M23 9LT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>People over the age of 60 who have fractured their hip.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>People who do not satisfy the inclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression in orthopaedic patients</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Cognitive behaviour therapy (CBT) for prevention and nurse intervention for treatment versus no intervention</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16863598 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="eccdacea-a14f-482c-9921-eef6b731ab11" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16863598"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13467-0</funderId>
      <contactId>Contact51115_13467</contactId>
      <sponsorId>Sponsor49513</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51115_13467">
    <title>Prof</title>
    <forename>Alistair</forename>
    <surname>Burns</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Wythenshawe Hospital
</address>
      <city>Manchester</city>
      <country>United Kingdom</country>
      <zip>M23 9LT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49513">
    <organisation>University of Manchester (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Wythenshawe Hospital</address>
      <city>Manchester</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>M23 9LT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5379.8</gridId>
    <rorId>https://ror.org/027m9bs27</rorId>
  </sponsor>
  <funder id="Funder13467-0">
    <name>Health Foundation (UK) (ref: orthopaedic study)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-28T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-09-12T00:00:00.000Z">97145188</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Patient involvement in prostate cancer treatment decisions</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>How many and which patients want to choose their own radiation dose?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary outcome measure is choice acceptance. At the end of the interview, the patient is asked whether he wants to choose one of the two treatment options, or whether he wants to leave the decision to the physician. The response to this question is choice acceptance. Choice acceptance is confirmed by telephone 2 days later. This measure is obtained about 10 days after the first consultation.</primaryOutcome>
      <secondaryOutcome>1. Substitute preferences of physicians 
2. Quality of life measures
3. Decision evaluation measures 
4. Coping measures
5. Knowledge measures 
6. Treatment preferences</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics committee CWOM number 0012-0284. Ethics approval date 16 March 2001.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN97145188</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Dutch Cancer Society 2001-2379; NTR63</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d09c575d-28b0-4c73-977d-5dc5aaa0ebbd">
	  <name>Radboud University Nijmegen MC</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 HB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with prostate cancer referred for radiotherapy with curative intent are eligible.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Male</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>Labile personality structure, as assessed by the physicians, and lack of understanding of the Dutch language.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Prostate cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Prostate cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control group is usual care (150 patients). Intervention group is usual care plus decision aid (150 patients).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17634489 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="51cf5dbf-38a7-438e-bd6b-3ea83ba4e5bd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17634489"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13635-0</funderId>
      <contactId>Contact51311_13635</contactId>
      <sponsorId>Sponsor49712</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51311_13635">
    <title>Dr</title>
    <forename>PFM</forename>
    <surname>Stalmeier</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Radboud University Nijmegen MC
MTA 138
PO Box 9101</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)24 3610592</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.stalmeier@mta.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49712">
    <organisation>Dutch Cancer Society (The Netherlands)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>PO 75508</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1070 AM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5700500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rc@kwfkankerbestrijding.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453041.7</gridId>
    <rorId>https://ror.org/0368jnd28</rorId>
  </sponsor>
  <funder id="Funder13635-0">
    <name>Dutch Cancer Society</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-11T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-09-09T00:00:00.000Z">51767272</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised trial of empiric broad-spectrum antibiotics and invasive diagnostic techniques in the setting of Ventilator-Associated Pneumonia</title>
      <scientificTitle/>
      <acronym>VAP</acronym>
      <studyHypothesis>To evaluate whether the use of two empiric broad-spectrum antibiotics and invasive diagnostic techniques will improve clinical resolution, decrease length of stay and reduce mortality of critically ill patients with a clinical suspicion of late Ventilator-Associated Pneumonia (VAP).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mortality at 28 days.</primaryOutcome>
      <secondaryOutcome>1. Duration of stay in ICU
2. Adjudicated diagnosis of pneumonia
3. Clinical and microbiological response to treatment
4. Adequacy of initial treatment
5. Emergence of resistant organisms
6. Candida colonization and infection
7. Multiple organ dysfunction
8. Duration of mechanical ventilation
9. Hospital length of stay
10. Antibiotic use and costs of care</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Queen's University Health Sciences &amp; Affiliated Teaching Hospitals Research Ethics Board on the 12th October 1999.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN51767272</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-50377</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4a33a12b-5351-437a-8080-d9d77af1fc4f">
	  <name>Kingston General Hospital</name>
	  <address/>
	  <city>Kingston</city>
	  <state/>
	  <country>Canada</country>
	  <zip>K7L 2V7</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients greater than or equal to 16 years old, either sex
2. Greater than 96 hours in the Intensive Care Unit (ICU)
3. Mechanically ventilated (greater than or equal to 48 hours)
4. Develops a clinical suspicion of pneumonia while ventilated</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>740</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>740</totalTarget>
      <exclusion>1. Unstable candidate for bronchoscopy as defined by the bronchoscopist
2. Patients not expected to survive greater than 72 hours or anticipate withdrawing treatments within 72 hours from the point of randomisation
3. Known or suspected history of anaphylaxis to penicillins, cephalosporins, carbapenems, meropenem or ciprofloxacin
4. Women who are pregnant or lactating
5. Patients already infected or colonised (respiratory tract only) with an organism not sensitive to study drugs
6. Patients already infected with pseudomonas species
7. Already on study drugs
8. Immunocompromised (post-organ transplantation, Human Immunodeficiency Virus [HIV], neutropenic [less than 1000 absolute neutrophils], corticosteroids [greater than 20 mg/day of prednisone or equivalent for more than 6 months])
9. Prior randomisation in this study
10. Enrolment in other interventional study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Clinical suspicion of ventilator associated pneumonia in critically ill patients</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Pneumonia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will undergo bronchoscopy with bronchoalveolar lavage or endotracheal aspirates. Following sampling patients will be randomised again to receive either meropenem and ciprofloxacin or meropenem alone.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Broad-spectrum antibiotics</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17182987 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7dc4e4fd-e32f-4dfe-aa13-a4e8114f70e0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-21T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17182987"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13560-0</funderId>
      <funderId>Funder13560-1</funderId>
      <funderId>Funder13560-2</funderId>
      <funderId>Funder13560-3</funderId>
      <contactId>Contact51227_13560</contactId>
      <sponsorId>Sponsor49629</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51227_13560">
    <title>Dr</title>
    <forename>Daren Keith</forename>
    <surname>Heyland</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kingston General Hospital
76 Stuart St
Angada 4 Rm 5-416</address>
      <city>Kingston</city>
      <country>Canada</country>
      <zip>K7L 2V7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 549 6666 ext. 3339</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dkh2@post.queensu.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49629">
    <organisation>Queen&#146;s University (Canada)</organisation>
    <website>http://www.queensu.ca/homepage/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Fleming Hall 
Jemmett Wing</address>
      <city>Kingston</city>
      <country>Canada</country>
      <zip>K7L 2V7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 533 6081</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">marlins@post.queensu.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410356.5</gridId>
    <rorId>https://ror.org/02y72wh86</rorId>
  </sponsor>
  <funder id="Funder13560-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-50377)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13560-1">
    <name>Physician Services Inc. (PSI) (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13560-2">
    <name>Bayer (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13560-3">
    <name>AstraZeneca (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/100004325</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-09-07T00:00:00.000Z">31371499</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Dexamethasone adjuvant therapy and intramuscular ceftriaxone in bacterial meningitis amongst adults in an area of high human immunodeficiency virus (HIV) prevalence in Blantyre, Malawi</title>
      <scientificTitle/>
      <acronym>SAM Trial (Steroids in Adult Meningitis)</acronym>
      <studyHypothesis>1. Dexamethasone, by limiting the host inflammatory response in bacterial meningitis, will reduce mortality and morbidity
2. Ceftriaxone is as effective given intramuscularly (IM) as it is when given intravenously (IV) and may therefore be used in rural areas where IV therapy is unavailable</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mortality at 40 days</primaryOutcome>
      <secondaryOutcome>1. Death or disability at 40 days
2. Clinically apparent hearing loss at 40 days
3. Death at six months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31371499</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P.98/99/30R</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>Malawi</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bff7ca7d-e031-4705-9680-bb1b74983e6d">
	  <name>27 Oatlands Rd</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX2 0EU</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All adults admitted to the Queen Elizabeth Central Hospital, Blantyre with a preliminary diagnosis of bacterial meningitis.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>420</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>420</totalTarget>
      <exclusion>1. Age less than 16 years
2. Steroids received within the 24 hours preceeding admission</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bacterial Meningitis</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Meningitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Dexamethasone 16 mg twice daily for 4 days versus placebo.
Ceftriaxone 2 mg twice daily for ten days given either IV or IM.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dexamethasone, ceftriaxione</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/18077809 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0a69ba11-b292-45d1-9cc7-21f438f8f0cf" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-12-13T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/18077809"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13373-0</funderId>
      <contactId>Contact51000_13373</contactId>
      <sponsorId>Sponsor49391</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51000_13373">
    <title>Dr</title>
    <forename>Matthew</forename>
    <surname>Scarborough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>27 Oatlands Rd</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX2 0EU</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mattscar@talktalk.net</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49391">
    <organisation>College of Medicine Research Committee (Malawi)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Private Bag 360
Chichiri</address>
      <city>Blantyre</city>
      <country>Malawi</country>
      <zip>BT3</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10595.38</gridId>
    <rorId>https://ror.org/04vtx5s55</rorId>
  </sponsor>
  <funder id="Funder13373-0">
    <name>Meningitis Research Foundation (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000403</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-11T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-09-01T00:00:00.000Z">58144540</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Increasing physical activity in obese children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Compared to children with free access to targeted sedentary behaviors, children with contingent access to sedentary behavior will exhibit greater increases in physical activity, larger reductions in sedentary behaviors, and more favorable changes in fitness, body composition, diet, and motivation to be physically active.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Physical activity, measured by pedometer counts.</primaryOutcome>
      <secondaryOutcome>1. Time in sedentary behaviour
2. Aerobic fitness (peak maximal oxygen consumption)
3. Body Mass Index (BMI)
4. Percent body fat (bioelectrical impedance and skinfold measurement)
5. Food intake and macronutrient composition
6. Motivation to be physically active (self-report)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Children's Hospital of Eastern Ontario (CHEO) Research Ethics Board on the 11th June 2001.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58144540</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-53574</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8d774c45-8f27-428a-9f3b-2bc8f37f8cc4">
	  <name>Children's Hospital of Eastern Ontario</name>
	  <address/>
	  <city>Ottawa, Ontario</city>
	  <state/>
	  <country>Canada</country>
	  <zip>K1H 8L1</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 8 - 12 year old children, either sex, who are overweight or obese defined as a Body Mass Index (BMI) above the 85th BMI percentile for age and sex (CDC, 2002)
2. Engaging in 15 hours of targeted sedentary behaviour per week, including TV/VCR/DVD use and video game playing
3. Engaging in less than 30 minutes of moderate to vigorous physical activity
4. No conditions that would limit physical activity
5. Agreement that the child or parent would not participate in any other exercise or weight control program during the course of the study
6. No regular participation in swimming or strength training because these activities cannot be measured properly by accelerometry
7. Willingness of the parents to enforce or maintain the contingencies or lack of as reflected by their assigned study group
8. Parent providing signed informed consent, and child providing signed informed assent</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="8.0"/>
      <upperAgeLimit unit="Years" value="12.0"/>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>48</totalTarget>
      <exclusion>Children with developmental disabilities, who are often obese, will be excluded from participating in this initial trial in order to reduce the heterogeneity of the sample.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obesity</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Obesity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: Contingent Group - 
The experimental (contingent) group is designed to increase child physical activity levels and decrease time spent in targeted sedentary behaviors by making access to sedentary activity contingent on physical activity. After data from activity monitors are downloaded, participants in the experimental contingent group will be told how much time they earned in each of the following two weeks for TV/VCR viewing and video games played via TV (e.g. Nintendo etc.). Parents will be taught how to program the TV allowance, which is an electronic device that records and helps budget TV/VCR viewing and video game playing. We acknowledge that targeted children may watch TV with parents or friends outside the house, or play computer games on a PC computer, and this will be measured by the concomitant use of self-report measures of sedentary activity. It is important to note that these potential sources of contamination also existed in previous clinical research that reduced access to TV viewing in obese children, and marked increases in physical activity were still obtained. Parents will be asked to implement the contingencies for two weeks beyond 12-week post-treatment to encourage physical activity between weeks 10 and 12, and this fading of contingency management may provide an opportunity for parents to implement their own contingencies. 

Control: Non-Contingent group -
Participants in the non-contingent control group will also visit the laboratory bi-weekly to have their physical activity monitors downloaded. They will also be given a TV allowance for monitoring purposes (and to control for this device in the home), but parents will be explicitly told that children should have free access to targeted sedentary activities independent of physical activity. The control group is designed to control for contact with investigators, feedback on physical activity levels, passage of time, the effects of wearing the activity monitors, and the presence of the TV allowance in the home.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13457-0</funderId>
      <contactId>Contact51100_13457</contactId>
      <sponsorId>Sponsor49503</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51100_13457">
    <title>Dr</title>
    <forename>Gary Scott</forename>
    <surname>Goldfield</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Children's Hospital of Eastern Ontario
Research Institute</address>
      <city>Ottawa, Ontario</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 737 7600 ext. 3288</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ggoldfield@cheo.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49503">
    <organisation>Children's Hospital of Eastern Ontario (Canada)</organisation>
    <website>http://www.cheo.on.ca/english/hub.shtml </website>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>401 Smyth Road</address>
      <city>Ottawa, Ontario</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.414148.c</gridId>
    <rorId>https://ror.org/05nsbhw27</rorId>
  </sponsor>
  <funder id="Funder13457-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-53574)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-29T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-08-26T00:00:00.000Z">95608630</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intensive insulin therapy does not alter the inflammatory response in patients undergoing coronary artery bypass graft (CABG): a randomized controlled trial</title>
      <scientificTitle/>
      <acronym>CH0401</acronym>
      <studyHypothesis>Strict glucose control in critically ill patients alters the cytokine balance towards a more pro-inflammatory state.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Cytokine levels</primaryOutcome>
      <secondaryOutcome>Complement concentration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN95608630</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CH0401</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4a303d87-bf2d-4c53-acc0-40eb50d4efe6">
	  <name>Geert Grooteplein 10</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 HB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adults, after uncomplicated CABG
2. Non-diabetics</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Diabetes
2. Renal failure
3. Use of anti-inflammatory drugs
4. Recent myocardial ischemia</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary artery bypass graft</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Coronary artery bypass graft</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Strict glucose control (blood glucose between 80-110 mg/dl) versus placebo (blood glucose &gt;200 mg/dl).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Insulin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16356228 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="51a225d4-314f-4cdf-b693-784caec8807e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16356228"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13411-0</funderId>
      <contactId>Contact51049_13411</contactId>
      <sponsorId>Sponsor49443</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51049_13411">
    <title>Dr</title>
    <forename>Cornelia</forename>
    <surname>Hoedemaekers</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Geert Grooteplein 10</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">C.Hoedemaekers@ic.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49443">
    <organisation>Radboud University Nijmegen Medical Centre (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Geert Groteplein 10</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)24 3617273</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">H.vanderHoeven@ic.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.10417.33</gridId>
    <rorId>https://ror.org/05wg1m734</rorId>
  </sponsor>
  <funder id="Funder13411-0">
    <name>The Department of Intensive Care, Radboud University Nijmegen Medical Centre</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-08-22T00:00:00.000Z">13438073</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A pragmatic cluster randomised controlled trial of a guideline-based educational outreach intervention to improve quality of adult respiratory care in South African primary care clinics: the PALSA (Practical Approach to Lung Health in South Africa) trial</title>
      <scientificTitle/>
      <acronym>PALSA (Practical Approach to Lung Health in South Africa)</acronym>
      <studyHypothesis>The trial was undertaken to test whether PALSA improves the quality of respiratory care for patients with cough and/or difficult breathing in real world primary care clinics.

Priority respiratory diseases among adults attending primary care services, including tuberculosis (TB), lower and upper respiratory tract infections, obstructive lung disease (asthma and chronic obstructive pulmonary disease), and human immunodeficiency virus (HIV) co-infection.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Sputum testing for tuberculosis
2. Inhaled corticosteroid prescriptions
3. Antibiotic prescriptions
4. Cotrimoxazole prescription among patients with tuberculosis</primaryOutcome>
      <secondaryOutcome>1. TB case detection
2. Mortality
3. Smoking cessation advice received
4. Smoking cessation
5. Readiness to quit smoking
6. Frequency and severity of respiratory symptoms
7. Health-related quality of life (Euroqol)
8. Health care utilisation
9. Cost of care</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 13/08/2007: The study was approved by the research ethics committee of the Faculty of Health Sciences, University of the Free State. The Free State Department of Health gave permission for the trial.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13438073</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-04-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-11-29T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8a9f32b0-320c-4f6c-8527-41d5995c8a11">
	  <name>Institute for Clinical Evaluative Sciences</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M4N 3M5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Forty primary care clinics in a high tuberculosis and HIV burden province of South Africa (Free State). Data will be collected from patients 15 years and older who provide written consent and who present with any one of the following:
1. Difficult breathing on the day of interview or during the last 6 months
2. Current cough for 7 days or more
3. Recurrent cough in the last 6 months
4. Current cough and a temperature in excess of 38°C and/or a respiratory rate of 30 breaths per minute or more</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1999</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40 primary care clinics, 1999 patients</totalTarget>
      <exclusion>Patients referred elsewhere urgently by their nurse practitioner will be excluded.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-04-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-11-29T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Respiratory diseases</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Cough and/or difficult breathing</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Educational outreach to groups of intervention clinic nurse practitioners, based on a clinical practice guideline on integrated adult respiratory case management and delivered with accompanying support materials.

Prescribing provisions for intervention clinic nurse practitioners will be expanded to include cotrimoxazole prophylaxis for symptomatic HIV infection, inhaled steroids for asthma (with review by a physician within one month) and a short course of oral corticosteroids for exacerbations of obstructive lung disease.

Control clinic nurse practitioners will receive no new training. Usual training, received by both intervention and control groups, includes short off-site training on the use of essential drugs including asthma medications and antibiotics, and the national TB protocol. Due to staff and budget restrictions, fewer than 5% of staff in any year attend these courses.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Inhaled corticosteroids, antibiotics, cotrimoxazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16195293 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0a38b97b-e118-4f95-baca-20858dda4020" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16195293"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13044-0</funderId>
      <funderId>Funder13044-1</funderId>
      <funderId>Funder13044-2</funderId>
      <funderId>Funder13044-3</funderId>
      <contactId>Contact50575_13044</contactId>
      <sponsorId>Sponsor48955</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50575_13044">
    <title>Dr</title>
    <forename>Merrick</forename>
    <surname>Zwarenstein</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Clinical Evaluative Sciences
G1 06
2075 Bayview Ave</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M4N 3M5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 4804055 ext. 7439</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">merrick.zwarenstein@ices.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48955">
    <organisation>University of Cape Town Lung Institute (South Africa)</organisation>
    <website>http://www.lunginstitute.co.za/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 34560
Groote Schuur</address>
      <city>Cape Town</city>
      <country>South Africa</country>
      <zip>7937</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.7836.a</gridId>
    <rorId>https://ror.org/03p74gp79</rorId>
  </sponsor>
  <funder id="Funder13044-0">
    <name>International Development Research Centre (Canada) (IDRC File No. 101489)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000193</fundRef>
  </funder>
  <funder id="Funder13044-1">
    <name>Free State Department of Health (South Africa)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13044-2">
    <name>Medical Research Council (South Africa)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
  <funder id="Funder13044-3">
    <name>University of Cape Town Lung Institute (South Africa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-08-16T00:00:00.000Z">20244858</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Six-week high-intensity exercise program for middle-aged patients with knee osteoarthritis: a randomized controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Short-term high-intensity exercise improves self-reported pain, function and quality of life in middle-aged patients with moderate to severe knee osteoarthritis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Knee injury and Osteoarthritis Outcome Score (KOOS, a disease specific questionnaire, assessing pain, other symptoms, activities of daily living, sport and recreation function and knee-related quality of life). Time points of interest were 6 weeks and 6 months.</primaryOutcome>
      <secondaryOutcome>1. 36-item short form health survey (SF-36, a generic measure of general health status)
2. Five tests of functional performance: 
2.1. Åstrands bicycle-ergometre test
2.2. Rising on one leg from sitting on lowest possible height
2.3. One-leg hop
2.4. Lateral step-up
2.5. One-leg semi squatting
2.6. Heel-rising on one leg</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Research Ethics Committee at Lund University (Sweden) (ref: LU 99-98), and is in compliance with the Helsinki Declaration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20244858</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-10-09T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-10-08T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="11546ad6-a0af-4630-8d4e-74cb5c56e4e3">
	  <name>Spenshult Hospital for Rheumatic Diseases</name>
	  <address/>
	  <city>Oskarström</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>S-313 92</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 35 - 65 years
2. Living in a defined geographic area
3. Diagnosis of radiographic knee osteoarthritis according to Kellgren &amp; Lawrence grade III or more (i.e joint space narrowing and definite osteophytes)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>61</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>61</totalTarget>
      <exclusion>1. Inflammatory joint disease
2. Anterior cruciate ligament injury
3. Known symptomatic injury to the menisci
4. Hip symptoms more aggravating than the knee symptoms
5. About to have knee replacement surgery within 6 months
6. Co-morbidities not allowing exercise</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-10-09T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-10-08T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Knee osteoarthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis (OA)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A six-week high-intensity supervised exercise session twice a week, or a non-intervention control group.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15924620 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5aeef8f6-d6f5-45a1-9853-1c346b9bcec0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-30T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15924620"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13365-0</funderId>
      <funderId>Funder13365-1</funderId>
      <funderId>Funder13365-2</funderId>
      <funderId>Funder13365-3</funderId>
      <funderId>Funder13365-4</funderId>
      <contactId>Contact50988_13365</contactId>
      <sponsorId>Sponsor49380</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50988_13365">
    <title>Dr</title>
    <forename>Ingemar</forename>
    <surname>Petersson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Spenshult Hospital for Rheumatic Diseases</address>
      <city>Oskarström</city>
      <country>Sweden</country>
      <zip>S-313 92</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ingemar.petersson@spenshult.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49380">
    <organisation>The Swedish Rheumatism Association (Sweden)</organisation>
    <website>http://www.reumatikerforbundet.org</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Alströmergatan 39
Box 12851</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>S-112 98</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jan.bagge@reumatikerforbundet.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.484681.7</gridId>
    <rorId>https://ror.org/00zps9v98</rorId>
  </sponsor>
  <funder id="Funder13365-0">
    <name>The Vårdal Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13365-1">
    <name>The Swedish Rheumatism Association in Stockholm (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13365-2">
    <name>The Swedish Rheumatism Association in Gothenburgh (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13365-3">
    <name>The Swedish Research Council (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13365-4">
    <name>The Department of Research and Development at Spenshult Hospital for Rheumatic Diseases (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-08-02T00:00:00.000Z">74481308</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Chronic and Acute Effects of Artificial Colourings and Preservatives on Children's Behaviour</title>
      <scientificTitle/>
      <acronym>FABiC - Food And Behaviour in Children</acronym>
      <studyHypothesis>1. Do children show a behavioural response to the withdrawal and introduction of artificial food colourings and preservatives (AFCPs)?
2. What are the characteristics that differentiate responders to AFCPs and non-responders &#150; baseline attention deficit hyperactivity disorder (ADHD) symptom severity and/or their genotype?
3. Can any response that is found in the stage one trial be replicated in a blind acute challenge?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Direct observation of classroom behaviour
2. Parent and teacher ratings of hyperactive behaviour
3. Continuous performance test assessment of sustained attention</primaryOutcome>
      <secondaryOutcome>Sleep</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74481308</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>pwh/ab/16/1/2491</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0ab050b9-3403-4497-be86-58899b98f6e5">
	  <name>School of Psychology</name>
	  <address/>
	  <city>Southampton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SO17 1BJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Stage 1 - Chronic exposure - 120 three year old children and 120 eight year old children from the general population.
Stage 2 - Acute exposure - 45 eight year old children selected as being responders or non-responders in the Stage 1 challenge.</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="3.0"/>
      <upperAgeLimit unit="Years" value="8.0"/>
      <gender>Both</gender>
      <targetEnrolment>297</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>153 3 year-olds and 144 8/9 year-olds</totalTarget>
      <exclusion>Those on special diets.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyperactivity</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Hyperactivity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A within subject double blind food challenge exposure to two additive mixes and one placebo mix - all children receiving all mixtures in a randomised order</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Artificial food colourings and preservatives (AFCPs)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17825405/ Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0a0bd005-bd8b-4445-bf68-d5212b4d137d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17825405/"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13243-0</funderId>
      <contactId>Contact50836_13243</contactId>
      <sponsorId>Sponsor49230</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50836_13243">
    <title>Prof</title>
    <forename>Jim</forename>
    <surname>Stevenson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Psychology
University of Southampton
Highfield</address>
      <city>Southampton</city>
      <country>United Kingdom</country>
      <zip>SO17 1BJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)23 8059 2583</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jsteven@soton.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49230">
    <organisation>University of Southampton (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Research Support Office
University of Southampton
Highfield</address>
      <city>Southampton</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>SO17 1BJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)23 8059 8672</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@rso.soton.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5491.9</gridId>
    <rorId>https://ror.org/01ryk1543</rorId>
  </sponsor>
  <funder id="Funder13243-0">
    <name>Food Standards Agency (UK) (Grant T07040)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000354</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-07-22T00:00:00.000Z">07092892</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double blind study of dexamethasone for the treatment of H5N1 Avian Influenza</title>
      <scientificTitle/>
      <acronym>DL Study</acronym>
      <studyHypothesis>We have started to see new cases of H5N1 infection. Five new cases confirmed in the last week all from different provinces of southern Viet Nam suggesting widespread (and therefore difficult to control) distribution of the virus. We suspect that this epidemic will prove more extensive than 2004. There is more than 80% mortality in the confirmed cases and most severe cases have been in children and teenagers. All patients are managed in a dedicated ward with barrier nursing and medical care. All patients are treated with oseltamivir for five days. Some patients have been given steroids some have not. There is no evidence on which to guide treatment, drugs, doses or duration. We have documented massive cytokine release in the patients from 2004. Our TaqMan real time Polymerase Chain Reaction (PCR) results are available within 24 hours of a sample being taken.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mortality</primaryOutcome>
      <secondaryOutcome>1. Duration of ventilation
2. Duration of supplemental oxygen
3. Duration of hospitalisation
4. Viral load in clinical specimens
5. Cytokine levels
6. Adverse effects</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07092892</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>061330</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned>No patients with H5N1 in Viet Nam since August 2005, only four patients recruited in total.  Data being analysed.</reasonAbandoned>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Viet Nam</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5910c1d6-1487-4f32-afea-cd2230415b24">
	  <name>Hospital for Tropical Diseases</name>
	  <address/>
	  <city>Ho Chi Minh City</city>
	  <state/>
	  <country>Viet Nam</country>
	  <zip>5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with confirmed TaqMan Influenza A positive, or H5N1 PCR
2. Patients with history of clear close exposure to sick poultry, Chest X-Ray changes consistent with H5N1, low white count and strong clinical suspicion of H5N1 infection</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>4</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>4 - recruitment terminated as not enough patients</totalTarget>
      <exclusion>No consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Avian Influenza</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Avian influenza</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Dexamethasone</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dexamethasone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13264-0</funderId>
      <contactId>Contact54113_13264</contactId>
      <sponsorId>Sponsor49275</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54113_13264">
    <title>Dr</title>
    <forename>Jeremy</forename>
    <surname>Farrar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hospital for Tropical Diseases
The Hospital for Tropical Diseases
Oxford University Clinical Research 
190 Ben Ham Tu</address>
      <city>Ho Chi Minh City</city>
      <country>Viet Nam</country>
      <zip>5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+84 8 836 2225</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jeremyjf@hcm.vnn.vn</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49275">
    <organisation>University of Oxford (UK)</organisation>
    <website>http://www.ox.ac.uk</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>University Offices
Wellington Square</address>
      <city>Oxford</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>OX1 2JD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4991.5</gridId>
    <rorId>https://ror.org/052gg0110</rorId>
  </sponsor>
  <funder id="Funder13264-0">
    <name>The Wellcome Trust (UK) (grant ref: 061330)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-07-22T00:00:00.000Z">83988447</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effects of intestinal helminth infections in early childhood on immune response, inflammation, anaemia and malnutrition</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To test whether anthelminthic treatment of children six to 36 months of age decreases severe anaemia, decreases wasting malnutrition, and decreases anorexia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Haemoglobin less than 70 g/l
2. Mid upper arm circumference less than -2 Z scores of international reference
3. Maternal report of anorexia</primaryOutcome>
      <secondaryOutcome>1. Weight-for-height less than -1 Z scores of international reference
2. Height-for-age less than -2 Z scores on international reference
3. Inflammation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83988447</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>063122</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Tanzania</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9c1b562b-4021-4306-83a4-4c24c39c37f7">
	  <name>Cornell University</name>
	  <address/>
	  <city>Ithaca NY</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>14853</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Six to 24 months of age
2. Informed consent
3. Residing in selected communities based on geographic catchment area</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Months" value="24.0"/>
      <gender>Both</gender>
      <targetEnrolment>2500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2500</totalTarget>
      <exclusion>1. Haemoglobin less than 70 g/l
2. Refusal of informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Anaemia, protein-energy malnutrition, anorexia</description>
	<diseaseClass1>Haematological Disorders</diseaseClass1>
	<diseaseClass2>Anaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Double blind Randomised Controlled Trial (RCT) of mebendazole versus an identical-looking but inert placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mebendazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder13269-0</funderId>
      <funderId>Funder13269-1</funderId>
      <contactId>Contact50883_13269</contactId>
      <sponsorId>Sponsor49263</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50883_13269">
    <title>Ms</title>
    <forename>Rebecca J</forename>
    <surname>Stoltzfus</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cornell University
Division of Nutritional Sciences
120 Savage Hall</address>
      <city>Ithaca NY</city>
      <country>United States of America</country>
      <zip>14853</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 607 255 7671</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rjs62@cornell.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49263">
    <organisation>Cornell University (USA)</organisation>
    <website>http://www.cornell.edu/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Division of Nutritional Sciences

</address>
      <city>Ithaca, NY</city>
      <country>United States of America</country>
      <zip>14853</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 607 255 2946</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">crf1@cornell.edu</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.5386.8</gridId>
    <rorId>https://ror.org/05bnh6r87</rorId>
  </sponsor>
  <funder id="Funder13269-0">
    <name>The Wellcome Trust (UK) (grant ref: 063122)</name>
    <fundRef/>
  </funder>
  <funder id="Funder13269-1">
    <name>Burroughs Wellcome Initiative (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-06T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">35617647</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessing three day pentamidine for early stage human African trypanosomiasis (Angola)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pharmacokinetic studies have shown that pentamidine has a large volume of distribution and elimination occurs over a long period. The objective of the study is to assess the efficacy of 3 days Intramuscular (IM) pentamidine treatment compared to the standard 7 days IM pentamidine treatment regimen.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of cases with favourable progress at 6 months, based on clinical state and laboratory status.</primaryOutcome>
      <secondaryOutcome>1. Proportion of cases with favourable progress at discharge, 3 and 12 months based on clinical state and laboratory status
2. Cure rate at 18 months, based on based on clinical state and laboratory status
3. Frequency and severity of adverse events</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. World Health Organization (WHO)/Ethics Review Committee (ERC) on the 4th December 2003
2. Instituto de Combate e Control o Das Triponosommiases (ICCT) (Angola) on the 18th October 2004
3. Wandsworth Local Research Ethics Committee (UK) on the 3rd December 2003</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35617647</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A30765</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-12-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Angola</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d25038bd-8fb8-4cea-91cc-1701144c27d9">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged more than or equal to 14 years and less than 60 years
2. Parasite positive (on examination of lymph juice, by Capillary Tube Centrifugation [CTC] or miniature Anion-Exchange Centrifugation [mAEC] on whole blood)
3. Alternative diagnoses excluded clinically and by appropriate laboratory investigations
4. Capable of and giving informed consent to the study</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>440</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>The total target was 440 patients, but only 18 were recruited in this site.</totalTarget>
      <exclusion>1. Stage II Human African Trypanosomiasis (HAT): defined as parasites in cerebrospinal fluid (CSF), or having more than or equal to 6 cells/mm^3 in CSF; or more than 100 red cells/mm^3 ("bloody tap")
2. Pregnant
3. Previous HAT
4. Known allergy or reactions to pentamidine
5. Diabetes mellitus
6. Difficulty to comply with follow-up (patients of no fixed abode and refugees, for example)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-12-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Human African Trypanosomiasis (HAT)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human African Trypanosomiasis (HAT)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This will be an open, randomised comparison of two pentamidine treatment regimens, given over three days or seven days with a non-inferiority trial design.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pentamidine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13006-0</funderId>
      <contactId>Contact50532_13006</contactId>
      <sponsorId>Sponsor48910</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50532_13006">
    <title>Dr</title>
    <forename>Melba</forename>
    <surname>Gomes</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gomesm@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48910">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder13006-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-03-10T00:00:00.000Z">11886401</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of rectal versus oral acetaminophen antipyresis in children</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>This randomised, double-dummy and placebo controlled study was conducted to compare the antipyretic efficacies of two different rectal doses of acetaminophen: 15 mg/kg and 35 mg/kg to that of a standard oral dose of 15 mg/kg, over a six-hour period, to allow detection of late antipyresis that may occur with rectal acetaminophen. The results of this study will provide further evidence on the comparative antipyretic efficacy of different doses of rectal acetaminophen versus the standard oral one.  

Our study hypothesis was that a single dose of 15 mg/kg oral acetaminophen is more effective than either 15 mg/kg or 35 mg/kg rectal acetaminophen, in reducing the temperature of febrile children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time to maximum antipyresis following administration of a single dose of acetaminophen.</primaryOutcome>
      <secondaryOutcome>Secondary outcomes included the temperatures at one, two, three, four, five, and six hours from administration and possible side effects such as hypothermia.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Institutional Review Board and the Ethics Committee at the American University of Beirut, as well as the Board of the Middle East Hospital, approved this study.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11886401</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Lebanon</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="954d6841-ae3e-4ed7-8f5f-d5670fe29ad7">
	  <name>American University of Beirut Medical Center</name>
	  <address/>
	  <city>Beirut</city>
	  <state/>
	  <country>Lebanon</country>
	  <zip>113-6044/C8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 6 months and 13 years
2. Rectal temperature greater than or equal to 38.5 °C
3. Consent of treating physician
4. Written consent of parent and oral consent of child if older than 10 years
5. No antipyretic intake for 8 hours prior to enrolment</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Years" value="13.0"/>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>48</totalTarget>
      <exclusion>1. Presence of concurrent or previous hepatic disease
2. Chronic and/or serious disease such as malignancy, septic shock, malabsorption syndromes etc.
3. Any condition interfering with the absorption of oral or rectal acetaminophen such as vomiting or severe diarrhoea, ileus, rectal bleeding etc.
4. Hypersensitivity to acetaminophen</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Fever</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Fever</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: A single dose of oral acetaminophen (15 mg/kg) plus placebo rectal suppository (size equivalent to a 35 mg/kg rectal acetaminophen suppository)
Group 2: A single dose of oral placebo (equivalent to a 15 mg/kg oral acetaminophen) plus a rectal suppository containing 15 mg/kg acetaminophen and 20 mg/kg placebo.
Group 3: A single dose of oral placebo as in group 2 plus a rectal suppository of 35 mg/kg acetaminophen.

Rectal temperature readings at baseline and hourly for a total of 6 hours.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Acetaminophen</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/16143048 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="20ba54d4-65aa-483a-a73e-58dabd3a5708" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-06T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16143048"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12917-0</funderId>
      <contactId>Contact50428_12917</contactId>
      <sponsorId>Sponsor48797</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50428_12917">
    <title>Dr</title>
    <forename>Mona</forename>
    <surname>Nabulsi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>American University of Beirut Medical Center</address>
      <city>Beirut</city>
      <country>Lebanon</country>
      <zip>113-6044/C8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+961 (0)3 628528</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mn04@aub.edu.lb</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48797">
    <organisation>American University of Beirut (Lebanon) </organisation>
    <website>http://www.aub.edu.lb/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Faculty of Medicine, Medical Practice Plan
Riyad El-Solh</address>
      <city>Beirut</city>
      <country>Lebanon</country>
      <zip>11-02-36</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+961 (0)1 350000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">resdean@aub.edu.lb</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.22903.3a</gridId>
    <rorId>https://ror.org/04pznsd21</rorId>
  </sponsor>
  <funder id="Funder12917-0">
    <name>American University of Beirut (Lebanon) - Medical Practice Plan of the Faculty of Medicine (grant ref: AUB A/C 686056)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-03-07T00:00:00.000Z">15342873</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Interventions to prevent falls and injury in elderly people with impaired vision</title>
      <scientificTitle/>
      <acronym>VIP Falls Prevention Trial</acronym>
      <studyHypothesis>Study objectives:
1. To demonstrate the efficacy of two interventions:
1.1. A strength and balance retraining programme and vitamin D supplements
1.2. A home safety programme, in preventing falls and injuries in people living in the community aged 75 years and over with visual impairment (visual acuity 6/24 or less)
2. To demonstrate the efficacy of the two programmes in improving independence, level of physical activity and quality of life
3. To determine the cost effectiveness of the two interventions in comparison with other falls prevention strategies
4. To determine the vitamin D status in a sample of people 75 years and over with visual impairment and compare this with an age and sex matched control group drawn from the same general practices at the same time

Summary of study design:
We will assess the effectiveness and cost effectiveness of two falls prevention programmes in a randomised controlled trial with one year of follow up. The two interventions will be individually delivered at home:
1. An exercise programme for one year consisting of a set of leg muscle strengthening and balance retraining exercises and a walking plan, modified for use by visually impaired people and individually prescribed by a physiotherapist. Participants in this intervention arm will also receive vitamin D (Calciferol) supplements.
2. An injury prevention programme of home safety assessment and modification designed specifically for visually impaired people and delivered by an occupational therapist.

We will recruit 400 men and women living in the community and aged 75 years and older with visual acuity of 6/24 metres or less. Potential participants will be recruited from low vision clinics at two city hospitals and one university department and from those registered with the Royal New Zealand Foundation for the Blind. 

The trial has a two by two factorial design. There will be 100 people randomly allocated to each of four groups:
1. The home exercise programme and vitamin D supplements, plus the home safety programme
2. The home exercise programme and vitamin D supplements
3. The home safety programme
4. A control group with no falls prevention intervention who will receive their usual care and health services, plus social visits.  

Falls, injuries and healthcare resource use as a result of falls will be monitored for one year.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Falls and injuries resulting from falls.</primaryOutcome>
      <secondaryOutcome>1. Self perceived health status (36-item short form health survey [SF-36])
2. Fear of falling
3. Physical activity level (human activity profile)
4. Visual disability (VF-14)
5. Mobility and physical independence (Nottingham extended activities of daily living [ADL])
6. Muscle strength and balance (4-test balance scale, chair stand test)
7. Use of health care resources as a result of falls and injuries
8. The incremental costs and cost effectiveness of delivering each intervention (if the intervention is effective in reducing falls)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Otago and Auckland Ethics Committees.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15342873</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>02/265</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="18d61978-7c48-4647-a552-6eca7d90f9e3">
	  <name>Department of Medical and Surgical Sciences</name>
	  <address/>
	  <city>Dunedin</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>9001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Community living women and men aged 75 years and older
2. Visual acuity 6/24 metres or less</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>391</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>391</totalTarget>
      <exclusion>1. Cannot walk around their own residence
2. Receiving physiotherapy at the time of recruitment
3. Cannot understand the trial requirements</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Falls in elderly people</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Falls</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Home environment programme
2. Home exercise programme
3. Both home environment and exercise programmes
4. Social visits</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16183652 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="0348c380-0ea5-4af5-9484-7aecd16eb7f4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-10-08T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16183652"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12913-0</funderId>
      <contactId>Contact50424_12913</contactId>
      <sponsorId>Sponsor48793</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50424_12913">
    <title>Prof</title>
    <forename>A John</forename>
    <surname>Campbell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Medical and Surgical Sciences
University of Otago Medical School
PO Box 913</address>
      <city>Dunedin</city>
      <country>New Zealand</country>
      <zip>9001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)3 4747007 ext. 8506</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">john.campbell@stonebow.otago.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48793">
    <organisation>Health Research Council of New Zealand (New Zealand)</organisation>
    <website>http://www.hrc.govt.nz/</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>PO Box 5541
Wellesley Street</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)9 379 8227</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@hrc.govt.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452999.a</gridId>
    <rorId>https://ror.org/00zbf3d93</rorId>
  </sponsor>
  <funder id="Funder12913-0">
    <name>Health Research Council of New Zealand (New Zealand) (ref: 02/265)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001505</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-02-15T00:00:00.000Z">04176397</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Procalcitonin guided reduction of the duration of antibiotic therapy in Community Acquired Pneumonia</title>
      <scientificTitle/>
      <acronym>ProCAP-Study/ProResp II-Study</acronym>
      <studyHypothesis>In patients with Community Acquired Pneumonia (CAP), guidelines recommend antibiotic treatment for 7 to 21 days. Procalcitonin is elevated in bacterial infections, and its dynamics have prognostic implications. 

Objective: 
To assess procalcitonin guidance for the initiation and duration of antibiotic therapy in community-acquired pneumonia. 

Hypothesis:
Procalcitonin guidance could significantly shorten antibiotic duration with a similar clinical and laboratory outcome.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Total antibiotic use, recorded on days 4, 6, and 8 and at follow-up after 6 weeks.</primaryOutcome>
      <secondaryOutcome>Measures of laboratory and clinical outcomes, recorded on days 4, 6, and 8 and at follow-up after 6 weeks.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the institutional review board of University Hospital Basel. Written, informed consent was obtained from all included patients or their legal representatives.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN04176397</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EKBB 232/03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="67654285-367f-40dc-a8a7-9db706b01ce4">
	  <name>University Hospital</name>
	  <address/>
	  <city>Basel</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>4031</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The criterion for inclusion in the study was a suspected CAP as the main diagnosis. This was defined as presence of a new infiltrate on chest X-ray accompanied by one or several acquired respiratory symptoms and signs:
1. Cough
2. Sputum production
3. Dyspnoea
4. Fever over 38.0°C
5. Auscultatory findings of abnormal breath sounds and rales
6. Leukocytosis more than 10 x 10^9 cells/L or leukopenia less than 4 x 10^9 cells/L in the absence of a hospital stay within 14 days before admission</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>250</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>250</totalTarget>
      <exclusion>1. Cystic fibrosis or active tuberculosis
2. Immunocompromised patients, i.e. patients infected with Human Immunodeficiency Virus (HIV) infection and a CD4 count below 200
3. Neutropenic patients with a neutrophil count less than 500 x 10^9/ml
4. Under chemotherapy with neutrophils 500 - 1000 x 10^9/ml with an expected decrease to values less than 500 x 10^9/ml
5. Immunosuppressive therapy after bone marrow or solid organ transplantation
6. Nosocomial pneumonia</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Community Acquired Pneumonia (CAP)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Pneumonia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Control group: 
Receive antibiotics according to usual practice.

Intervention group:
In the procalcitonin group, antibiotic treatment was based on serum procalcitonin concentrations as follows: 
1. Strongly discouraged: less than 0.1 µg/L
2. Discouraged: less than 0.25 µg/L
3. Encouraged: greater than 0.25 µg/L
4. Strongly encouraged: greater than 0.5 µg/L

Reevaluation of the clinical status and measurement of serum procalcitonin levels was recommended after 6 - 24 hours in all patients from whom antibiotics were withheld. Procalcitonin levels were reassessed after 4, 6, and 8 days. Antibiotics were discontinued on the basis of the procalcitonin cutoffs defined above. In patients with very high procalcitonin values on admission (e.g., greater than 10 µg/L), discontinuation of antibiotics was encouraged if levels decreased to levels less than 10% of the initial value (e.g., 1 µg/L, instead of less than 0.25 µg/L).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16805922
2006 Other publications in https://pubmed.ncbi.nlm.nih.gov/16603606
2007 Other publications in https://pubmed.ncbi.nlm.nih.gov/17702966</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="73351721-ff80-46eb-bfd7-e902f6165828" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-06-28T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16805922"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="a6a9cd0a-28bc-41f6-b367-b5d9f2c464da" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2006-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16603606"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="2c3e5b0c-f341-4022-b222-d22bb0eeb7aa" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17702966"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12858-0</funderId>
      <funderId>Funder12858-1</funderId>
      <funderId>Funder12858-2</funderId>
      <funderId>Funder12858-3</funderId>
      <funderId>Funder12858-4</funderId>
      <funderId>Funder12858-5</funderId>
      <funderId>Funder12858-6</funderId>
      <contactId>Contact50348_12858</contactId>
      <sponsorId>Sponsor48718</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50348_12858">
    <title>Prof</title>
    <forename>Beat</forename>
    <surname>Muller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Hospital
Petersgraben 4</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>4031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)61 265 2525</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Happy.Mueller@unibas.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48718">
    <organisation>University Hospital Basel (Switzerland)</organisation>
    <website>http://www.universitaetsspital-basel.ch/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Petersgraben 4</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>4031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)61 265 2525</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Happy.Mueller@unibas.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410567.1</gridId>
    <rorId>https://ror.org/04k51q396</rorId>
  </sponsor>
  <funder id="Funder12858-0">
    <name>University Hospital Basel (Switzerland):</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-1">
    <name>1. Clinic of Pulmonary Medicine</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-2">
    <name>2. Clinic of Endocrinology</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-3">
    <name>3. Emergency Unit</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-4">
    <name>4. Department of Internal Medicine</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-5">
    <name>5. Department of Central Laboratories (infrastructure)</name>
    <fundRef/>
  </funder>
  <funder id="Funder12858-6">
    <name>BRAHMS AG (Germany) - assay material</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-02-14T00:00:00.000Z">01928173</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>British study of Risedronate In Structure and symptoms of Knee osteoarthritis</title>
      <scientificTitle/>
      <acronym>BRISK</acronym>
      <studyHypothesis>To determine the efficacy and safety of risedronate in patients with knee Osteoarthritis (OA). The British study of Risedronate In Structure and symptoms of Knee osteoarthritis (BRISK), a 1-year prospective, double-blind, placebo-controlled study enrolled patients (40 - 80 years) with mild-to-moderate medial compartment knee OA. The primary aims were to detect differences in symptoms and function. Patients were randomised to once-daily risedronate (5 mg or 15 mg) or placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The outcome instrument for assessment of OA symptoms was evaluation of risedronate efficacy on symptoms of OA was the Western Ontario and McMaster Universities (WOMAC) OA index. The visual analogue scale (VAS) of the index was used, in which patients assessed each question using a 100 mm scale, with a higher score representing greater symptom severity. The total index score for the signal knee corresponded to the weighted composite of the 24 question scores standardised to a 100 point scale; scores were also determined for the subscales of pain (five questions), stiffness (two questions) and physical function (17 questions).

The outcome measure for assessment of joint structural changes was mean change from baseline in minimum JSW of the medial compartment of the knee. Radiographs of the knee were taken at baseline and at 1 year using a standardised radiographic method with fluoroscopic positioning of the joint in a semi-flexed position.</primaryOutcome>
      <secondaryOutcome>Other symptom outcome measures included a Patient Global Assessment (PGA) of disease, consumption of pain medication and the use of walking aids. For the PGA, patients answered the following question using a VAS: Considering all the ways your OA affects you, how have you been in the last 48 hours? Results for the question were expressed as values on a 0 - 100 mm scale.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The subjects gave their written, informed consent before entering the study, which was conducted in accordance with the International Conference on Harmonization (ICH) guidelines for Good Clinical Practice (GCP) and was approved by the UK Multicentre Research Ethical Committee (MREC).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN01928173</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2000024</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind, placebo-controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d55c88f2-945d-4cb5-835d-a2444fac43a3">
	  <name>Consultant Rheumatologist</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SE1 7EH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female subjects aged 40 - 80 years 
2. Mild-to-moderate medial-compartment knee OA
3. Diagnosed according to the clinical and radiological criteria of the American College of Rheumatology
4. OA in at least one knee, designated as the signal knee, was required to meet the following clinical and radiographic criteria.

Clinical inclusion criteria:
1. Presence of daily knee pain for at least 1 month out of 3 months prior to the study
2. At least one of the following: 
2.1. Age greater than 50 years old
2.2. Morning knee stiffness of less than 30 minutes
2.3. Knee crepitus

Radiographic criterion for inclusion:
1. A Joint-Space Width (JSW) of between 2 - 4 mm in the medial tibiofemoral compartment in the semi-flexed Anterior-Posterior (AP) view
2. A requirement for a narrower width than in the lateral compartment of the same knee 
3. Patients were also required to have at least one osteophyte in either the medial or lateral compartments of the tibiofemoral joint</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>285</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>285</totalTarget>
      <exclusion>1. The presence of rheumatic diseases that could be responsible for secondary OA
2. Use of intra-articular hyaluronic acid in the signal knee
3. Knee injury or diagnostic arthroscopy of the signal knee in the 6 months prior to enrolment
4. History of knee surgery (including arthroscopy requiring an incision of internal joint components) in the signal knee at any time
5. Intra-articular corticosteroids in the 3 months preceding enrolment
6. The presence of non-OA causes of knee pain in the signal knee (e.g. anserine bursitis, fibromyalgia and osteonecrosis)
7. Use of bisphosphonates within 12 months prior to enrolment</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis (OA)</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised to:
1. 5 mg of Risedronate
2. 15 mg of Risedronate 
3. Placebo 

Patients were treated once daily for one year.

Knee radiographs were performed at baseline and at one year, urine and serum samples were collected at baseline and at months three, six and twelve and the Western Ontario and McMaster Universities OA Index was also performed.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Risedronate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15899049 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e2395d24-7384-4472-99d7-a5201fe4f602" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-03-24T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15899049"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12891-0</funderId>
      <contactId>Contact50398_12891</contactId>
      <sponsorId>Sponsor48767</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50398_12891">
    <title>Prof</title>
    <forename>Tim</forename>
    <surname>Spector</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Consultant Rheumatologist
Professor of Genetic Epidemiology
Twin Research &amp; Genetic Epidemiology Unit
St Thomas Hospital</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE1 7EH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48767">
    <organisation>Procter and Gamble Pharmaceuticals (USA) </organisation>
    <website>http://www.pgpharma.com/index.shtml</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>-</address>
      <city>Mason, Ohio</city>
      <country>United States of America</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418758.7</gridId>
    <rorId>https://ror.org/04dkns738</rorId>
  </sponsor>
  <funder id="Funder12891-0">
    <name>Procter and Gamble Pharmaceuticals (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-01-17T00:00:00.000Z">57616765</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A multicenter, randomized, double-blind, placebo-controlled investigation of long-term safety and efficacy of LCAP (leukocytapheresis using "Cellsorba FX") in patients with refractory, chronic active ulcerative colitis</title>
      <scientificTitle/>
      <acronym>MICELL-UC</acronym>
      <studyHypothesis>Study hypothesis added as of 8 June 2007: Assessment of long-term safety and efficacy of leukocytapheresis with Cellsorba FX in comparison to sham-leukocytapheresis for patients with refractory, chronic active ulcerative colitis (CAI 6-10).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary outcome measures added as of 8 June 2007: 

The primary efficacy parameter is the 7-item Clinical Activity Index (CAI). A sum score will be calculated summing up all items that are differently weighted. The range of the sum score is 0 to 29 points. A sum score of less than four (or less than or equal to 4) points at the end of the therapy will be assessed as remission or success.</primaryOutcome>
      <secondaryOutcome>Secondary outcome measures added as of 8 June 2007: 

1. Inflammatory Bowel Disease Questionnaire (IBDQ), German translation. This questionnaire consists of four domains and 32 items. Domains are simply the sum of specific items, i.e. bowel symptoms, systemic symptoms, emotional functions and social functions.
2. Endoscopic Index (EI), which includes 4 items with different weights. The range of the sum score is 0 to 12 points.
3. Cumulative steroid dose over intensive and maintenance phase.
4. CAI, item-wise analysis.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval information added as of 8 June 2007: 

Approvals of the following ethics committees were obtained on 19 August 2004: 
1. Hannover Medical School (MHH)
2. University (LMU) of Munich
3. University of Erlangen
4. Medical association of Mecklenburg-Western Pomerania (Rostock)
5. University of Munster
6. Charité, University of Berlin
7. Medical association of Rhineland-Palatinate (Mainz)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN57616765</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1.6 - 07/2004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>The trial will be terminated due to unsatisfactory patient enrolment: during the scheduled period of 24 months, less than 50% of patient enrolment has been completed.</reasonAbandoned>
      <overallStartDate>2004-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c967e54f-7de2-4002-9719-9b5f04281aa6">
	  <name>Apheresis Research Institute</name>
	  <address/>
	  <city>Cologne</city>
	  <state/>
	  <country>Germany</country>
	  <zip>50935</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Ulcerative colitis with chronic active disease state
2. Colitis endoscopically covering at least 15 cm
3. Clinical Activity Index: 6-10
4. No long term remission using combined standard therapy including 5-Aminosalicylate (ASA), prednisolone and/or azathioprine
5. Cumulative steroid dosage within the last 2 months in total at least 600 mg
6. Steroid dosage constant 10 mg per day during 2 weeks before start of treatment (pre-treatment phase)
7. Negative test of pregnancy for female patients
8. Patient is able to understand and sign informed consent</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>95</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Planned number of recruitment added as of 8 June 2007: 95 (less than 50% achieved).</totalTarget>
      <exclusion>Exclusion criteria added as of 8 June 2007: 
1. Age &lt; 18 or ≥ 80 years 
2. Effective response to conventional Ulcerative Colitis (UC) therapy 
3. Diagnosis of proctitis or mild UC (usually controlled by aminosalicylates and suppository steroid therapies) 
4. Active symptoms which would exclude the patient from undergoing routine diagnostic colonoscopy i.e. evidence of active bowel obstruction, intestinal perforation, significant GI hemorrhage or known high-grade stricture 
5. Body weight is less than 40 kg 
6. Any malignant disease currently or in history 
7. Renal failure and/ or hepatic failure (Glutamate Oxalate Transferase [GOT], Glutamic-Pyruvic Transaminase [GPT], total billirubin, creatinine &gt; twice the normal value) 
8. Chronic hypotension (80 mmHg or lower systolic) 
9. Therapeutic anticoagulation (Cumarine) or coagulation disorder 
10. Active bacterial or viral infection, especially acute or chronic Hepatitis B or C virus infection, or HIV infection 
11. Severe cardiovascular disease (New York Heart Association [NYHA] III-IV or Canadian Cardiovascular Society [CCS] III-IV), which would not permit any extracorporeal treatment 
12. Breast feeding, pregnancy, drug abuse or dementia 
13. Participation in another clinical study in the last 3 months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Refractory, chronic active ulcerative colitis</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Ulcerative colitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Please note that this study was terminated on 25 April 2007 due to unsatisfactory patient enrolment. 

Interventions provided at registration:
Extracorporeal leukocytapheresis (LCAP; verum group) versus sham-leukocytaphersis (placebo group)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12783-0</funderId>
      <funderId>Funder12783-1</funderId>
      <contactId>Contact50247_12783</contactId>
      <sponsorId>Sponsor48618</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50247_12783">
    <title>Dr</title>
    <forename>Reinhard</forename>
    <surname>Klingel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Apheresis Research Institute
Stadtwaldgürtel 77</address>
      <city>Cologne</city>
      <country>Germany</country>
      <zip>50935</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49-221-406 317 0</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">afi@apheresis-research.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48618">
    <organisation>Asahi Kasei Medical Europe GmbH (Germany)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Lyoner strasse 44-48</address>
      <city>Frankfurt</city>
      <country>Germany</country>
      <zip>60528</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.492258.0</gridId>
    <rorId>https://ror.org/040cmp171</rorId>
  </sponsor>
  <funder id="Funder12783-0">
    <name>Source of funding added as of 8 June 2007:</name>
    <fundRef/>
  </funder>
  <funder id="Funder12783-1">
    <name>Asahi Kasei Medical Europe GmbH, Lyoner Strasse 44-48, 60528 Frankfurt (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-01-05T00:00:00.000Z">64013427</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Phase III study of safety, tolerance, efficacy, pharmacokinetics, and costs of therapy with voriconazole or placebo in the prophylaxis of lung infiltrates in patients undergoing induction chemotherapy for acute myelogenous leukaemia</title>
      <scientificTitle/>
      <acronym>Voriconazole prophylaxis</acronym>
      <studyHypothesis>Voriconazole is superior to placebo in the prophylaxis of lung infiltrates until day 21 after start of induction chemotherapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incidence of lung infiltrates</primaryOutcome>
      <secondaryOutcome>1. Incidence of fever and other signs of infection
2. Incidence and type of documented bacteremia
3. Rate of patients with systemic open-label antifungal therapy
4. Time to initiation of systemic open-label antifungal therapy
5. Duration of absolute neutrophil count &lt;500/µl
6. Rate and type of proven, probable and possible breakthrough invasive fungal infections
7. Rate of patients with fever of unknown origin
8. Incidence and severity of adverse events
9. Trough voriconazole plasma level 
10. Direct costs of systemic antibiotics, antifungals and antivirals and diagnostic imaging
11. Overall costs in terms of the diagnosis related groups applied to the study patients</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64013427</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NRA 150 0009</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>This trial was prematurely terminated on 19 January 2006 due to establishment of a new standard treatment, which made the placebo group of the trial ethically unjustifiable.</reasonAbandoned>
      <overallStartDate>2004-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a7edf721-40c1-465a-b9c8-78db8db61d3e">
	  <name>University Hospital of Cologne</name>
	  <address/>
	  <city>Cologne</city>
	  <state/>
	  <country>Germany</country>
	  <zip>50924</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with first induction chemotherapy for acute myelogenous leukaemia (AML):
1. Newly diagnosed or relapsed, de novo or secondary AML
2. First induction chemotherapy cycle
3. Expected neutropenic phase of a minimum duration of 10 days
4. Age greater than 18 years
5. Legally signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Planned: 150 patients, analyzed: 25 patients.</totalTarget>
      <exclusion>1. Known proven, probable or possible invasive fungal infection at randomization or in patient history
2. CT with any signs of a fungal infection according to the EORTC/MSG criteria, i.e. with any infiltrate (Ascioglu, et al 2002)
3. Any current fever unless explained by non-infectious causes 
4. Antibacterial prophylaxis other than TMP/SMX
5. LFT (AST/ALT/bilirubin) more than 3x the upper normal limit
6. Subjects who are receiving and cannot discontinue one of the following drugs at least 24 hours prior to randomization: 
6.1. Drugs with a known possibility of QTc prolongation (e.g. terfenadine, astemizole, cisapride, pimozide, quinidine)
6.2. Drugs whose plasma levels may be increased by voriconazole therapy (e.g. sulphonylureas, ergot alkaloids, sirolimus, vinca alkaloids) 
7. Subjects who have received the following drugs within 14 days prior to randomization: Potent inducers of hepatic enzymes that will reduce voriconazole levels (e.g. rifampicin, carbamazepine and barbiturates)
8. Concomitant therapy with absorbable antifungals
9. Patient has a diagnosis of acute hepatitis or cirrhosis due to any cause
10. Known hypersensitivity or other contraindication to voriconazole
11. Patient unwilling or unable to comply with the protocol
12. Diseases or disabilities preventing the patient from participating in the trial
13. Females of childbearing potential without negative serum pregnancy test at baseline or within 72 hours prior to start of study drug

Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002 Jan 1;34(1):7-14.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Acute Myelogenous Leukaemia (AML)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Leukaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Voriconazole 200 mg twice a day (bid) orally (po) or placebo

This trial was prematurely terminated on 19 January 2006 due to establishment of a new standard treatment, which made the placebo group of the trial ethically unjustifiable.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Voriconazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12362-0</funderId>
      <contactId>Contact49833_12362</contactId>
      <sponsorId>Sponsor48579</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact49833_12362">
    <title>Dr</title>
    <forename>Oliver</forename>
    <surname>Cornely</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Hospital of Cologne
Department of Internal Medicine</address>
      <city>Cologne</city>
      <country>Germany</country>
      <zip>50924</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 221 478 6209</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">oliver.cornely@uni-koeln.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48579">
    <organisation>University Hospital of Cologne (Germany)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Kerpener Strasse 62</address>
      <city>Cologne</city>
      <country>Germany</country>
      <zip>50924</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411097.a</gridId>
    <rorId>https://ror.org/05mxhda18</rorId>
  </sponsor>
  <funder id="Funder12362-0">
    <name>Pfizer GmbH, Karlsruhe (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-17T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-09-27T00:00:00.000Z">17448795</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Hereditary non-polyposis colorectal carcinoma (HNPCC) - a prospective randomized trial for the comparison of prophylactic or extended surgery versus oncological resection in colon or rectum carcinoma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17448795</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>70-2993 Oh 1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8920858c-d599-4518-804c-fbb762cee8c0">
	  <name>Klink für Allgemeine und Viszeralchirurgie</name>
	  <address/>
	  <city>Düsseldorf</city>
	  <state/>
	  <country>Germany</country>
	  <zip>40225</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Colorectal carcinoma fulfilling the Amsterdam-criteria for HNPCC or
2. Colorectal carcinoma in patients with known pathogenic mismatch repair gene mutation or
3. Colorectal carcinoma at the age of 50 or less and detection of microsatellite instability in a tumor biopsy and
4. Age between 18 and 65 years
5. Operability for subtotal colectomy/(restorative) proctocolectomy as estimated by the surgeon
6. Exclusion of metastases, local resection of the complete tumor likely to be possible
7. Elective tumorsurgical operation
8. Willingness of the patient to participate in surveillance required by the trial
9. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>HNPCC-associated colorectal carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Colorectal</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subtotal colectomy vs. oncologic resection (restorative proctocolectomy vs rectum resection/extirpation)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder11252-0</funderId>
      <contactId>Contact41695_11252</contactId>
      <sponsorId>Sponsor39440</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41695_11252">
    <title>Prof</title>
    <forename>Gabriela</forename>
    <surname>Möslein</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klink für Allgemeine und Viszeralchirurgie
Universitätsklinikum Düsseldorf</address>
      <city>Düsseldorf</city>
      <country>Germany</country>
      <zip>40225</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)211/81-16397</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">moeslein@uni-duesseldorf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39440">
    <organisation>Deutsche Krebshilfe e. V. - German Cancer Aid (Germany) </organisation>
    <website>http://www.krebshilfe.de/startseite-dkh.html</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Thomas-Mann-Strasse 40</address>
      <city>Bonn</city>
      <country>Germany</country>
      <zip>53004</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)228/72990-0</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">deutsche@krebshilfe.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453370.6</gridId>
    <rorId>https://ror.org/01wxdd722</rorId>
  </sponsor>
  <funder id="Funder11252-0">
    <name>Deutsche Krebshilfe e. V. (70-2993 Oh 1)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-07-12T00:00:00.000Z">51421587</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Swiss VISCOsupplementation Trial 1</title>
      <scientificTitle/>
      <acronym>SVISCOT-1</acronym>
      <studyHypothesis>To determine the comparative effectiveness, cost-utility and safety of preparations with different chemical structures and origins used for viscosupplementation in knee Osteoarthritis (OA).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Western Ontario and McMaster Universities osteoarthritis index (WOMAC) pain sub-scores.</primaryOutcome>
      <secondaryOutcome>Cost-utility based on health related quality of life measured by EuroQoL and self-reported healthcare utilisation for osteoarthritis</secondaryOutcome>
      <trialWebsite>http://www.ispm.unibe.ch/research/ongprojects_epstat/sviscot-1.html</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN51421587</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ed76c208-c8e3-4b84-9c11-eceed8f885f6">
	  <name>Departments of Social and Preventive Medicine and Rheumatology</name>
	  <address/>
	  <city>Berne</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>3012</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and non-pregnant women with radiologically confirmed symptomatic OA of the knee
for at least 6 months
2. Pain on most days for the previous 3 months
3. Fulfil American College of Rheumatology (ACR) clinical criteria for OA of the knee:
3.1. Have an ACR functional class rating of II to IV
3.2. Failed to respond sufficiently 
3.3. Intolerant to conservative treatment</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>Not provided at time of registration.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoarthritis (OA) of the knee</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoarthritis of the knee</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be allocated to one of three different preparations, a cross-linked formulation
(Synvisc®) and non-cross-linked preparations of different origin (Orthovisc® and Ostenil®).
Patients will undergo up to three treatment cycles per knee (one cycle consisting of three
injections), with not more than one treatment cycle per knee every 6 months and the last
injection administered not later than 18 months post-randomisation.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Orthovisc®, Ostenil®, Synvisc®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17968921 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="dee0db52-92fa-49cc-97a5-1529210695a9" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17968921"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11225-0</funderId>
      <funderId>Funder11225-1</funderId>
      <contactId>Contact41660_11225</contactId>
      <sponsorId>Sponsor39405</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41660_11225">
    <title>Dr</title>
    <forename>Peter</forename>
    <surname>Juni</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Departments of Social and Preventive Medicine and Rheumatology
University of Berne
Finkenhubelweg 11</address>
      <city>Berne</city>
      <country>Switzerland</country>
      <zip>3012</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">juni@ispm.unibe.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39405">
    <organisation>Swiss Federal Office of Social Insurance (OFAS) (Switzerland)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Effingerstrasse 20  </address>
      <city>Berne</city>
      <country>Switzerland</country>
      <zip>3003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.483062.b</gridId>
    <rorId>https://ror.org/03zv4m970</rorId>
  </sponsor>
  <funder id="Funder11225-0">
    <name>The Swiss Federal Office of Social Insurances (Switzerland) - funding protocol development and implementation</name>
    <fundRef/>
  </funder>
  <funder id="Funder11225-1">
    <name>The manufacturers do not provide any funding for the trial.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-17T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">15366053</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The impact of telephone and recorded delivery reminders on the response rate to research questionnaires</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15366053</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1996-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="91979152-5f5e-4444-9d6f-7361c17052fd">
	  <name>Primary Care and Population Sciences</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>N19 5NF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Non-responders of a larger randomised controlled trial</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>No telephone available</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1996-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Not applicable</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Telephone reminder
2. Recorded delivery reminder</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1997 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9243440 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="74599777-dc25-4e10-b044-337c7dd47c8a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1997-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9243440"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6009-0</funderId>
      <contactId>Contact7554_6009</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7554_6009">
    <title>Ms</title>
    <forename>Sharon</forename>
    <surname>See Tai</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Primary Care and Population Sciences
University College London Medical School
Whittington Hospital
Archway Campus</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>N19 5NF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6009-0">
    <name>NHS Executive London (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">60825437</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double blind randomised placebo controlled study to evaluate the efficacy of Enzyme Potentiated Desensitisation (EPD) in seasonal rhinitis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Is enzyme potentiated desensitisation significantly superior to an identical placebo treatment when administered pre-seasonally to hay fever sufferers?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Measured during 12 week hay fever season: number of problem free days and post-treatment symptom scores.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Southwest England Multicentre Research Ethics Committee (MREC) and several local research ethics committees.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN60825437</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>SEO131</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-05-14T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-08-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="96d982c8-721a-400e-9a5a-ce27f6a0dd10">
	  <name>Complementary Therapy Centre</name>
	  <address/>
	  <city>Southampton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SO14 OYG</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. To be recruited from GP lists aged 18 - 64 years
2. Either sex
3. History of seasonal allergic rhinitis extending mid-May to end-July
4. Positive skin prick test to mixed grass pollens</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240</totalTarget>
      <exclusion>1. Symptoms of sufficient severity to require regular treatment outside usual grass-pollinating season
2. History of predominant seasonal problem not corresponding with usual grass-pollinating season
3. Rhinitis complicated by nasal infection, rhino-sinusitis, nasal polyps, septal deviation, gross turbinate hypertrophy or intranasal mass
4. History of anaphylaxis or laryngeal oedema
5. Undergoing nasal surgery within 2 months
6. Receiving specific immunotherapy (high dose method) within preceeding 12 months</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-05-14T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-08-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Seasonal rhinitis</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Seasonal rhinitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients randomised to receive two injections out of hay fever season, either EPD or placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Enzyme Potentiated Desensitisation (EPD)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/18056902 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fbbdd162-dfff-4003-a39a-45bd37f347b5" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-12-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/18056902"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5969-0</funderId>
      <contactId>Contact7362_5969</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7362_5969">
    <title>Dr</title>
    <forename>George</forename>
    <surname>Lewith</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Complementary Therapy Centre
Royal South Hants Hospital
Brintons Terrace</address>
      <city>Southampton</city>
      <country>United Kingdom</country>
      <zip>SO14 OYG</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5969-0">
    <name>NHS Executive South East (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-17T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">16629331</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Overnight Calls in Primary Care - Randomized Controlled Trial of Management Using Nurse Telephone Consultation</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16629331</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f1f90098-188c-4240-9634-4c96fdcb0afb">
	  <name>Health Care Research Unit</name>
	  <address/>
	  <city>Southampton</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SO16 5NH</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients contacting the out of hours service or about whom contact was made during specified times over the trial year</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Not applicable</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A nurse telephone consultation service integrated within a general practice cooperative. The out of hours period was 6.15pm to 11.15pm from Monday to Friday, 11.00am to 11.15pm on Saturday, and 8.00am to 11.15pm on Sunday. Experienced and specially trained nurses received, assessed, and managed calls from patients or their carers. Management options included telephone advice; referral to the general practitioner on duty (for telephone advice, an appointment at a primary care centre, or a home visit); referral to the emergency service or advice to attend accident and emergency. Calls were managed with the help of decision support software.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1999 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10574857 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="775e9ba4-843e-4fb6-bcfb-1c8ac5fe1f4a" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1999-11-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10574857"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6174-0</funderId>
      <contactId>Contact7472_6174</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7472_6174">
    <title>Dr</title>
    <forename>Steve</forename>
    <surname>George</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Health Care Research Unit
Southampton General Hospital</address>
      <city>Southampton</city>
      <country>United Kingdom</country>
      <zip>SO16 5NH</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pluto@soton.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6174-0">
    <name>NHS Executive South West (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-17T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">16783552</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Do clinical guidelines introduced with practice based education improve care of asthmatic and diabetic patients?</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16783552</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1993-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1993-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="46d11777-1464-46bd-9f96-0b984f23cde3">
	  <name>Department of General Practice and Primary Care</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>EC1M 6BQ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Non-training GP practices in Hackney (East London).</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1993-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1993-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Nutritional, metabolic and endocrine diseases: Diabetes; Respiratory tract diseases: Asthma</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Each practice received a set of guidelines on either Diabetes or Asthma but provided management data for both</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1995 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8520339 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="cd2e5ddd-1864-49e8-9ed4-339bc6990846" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1995-12-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8520339"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6177-0</funderId>
      <contactId>Contact7361_6177</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7361_6177">
    <title>Dr</title>
    <forename>Gene</forename>
    <surname>Feder</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of General Practice and Primary Care
St Bartholomew's and Royal London Hospital Medical College</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>EC1M 6BQ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6177-0">
    <name>NHS Executive London (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-14T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">12144425</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of an hospital-based palliative care service in the community.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>This project aims to evaluate the cost and effectiveness of an hospital based palliative care service on subsequent care of advanced cancer patients in the community, in terms of length of index hospital admission, and need for re-admission, quality of symptom control on discharge and at home, quality of life and functional status at home, patient and carer satisfaction, impact on general practitioner/district nurse workload, and eventual place of death. The effects of such a service on the professional satisfaction of the primary care team will also be assessed. The study will be a randomised controlled trial of two levels of intervention by the palliative care team in the United Bristol Healthcare Trust. Assessments will be undertaken both during the hospital admission and after discharge over a 5 month follow-up period or to death.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12144425</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NCP/J01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fdfefaac-bcdf-4260-9162-625c4bbea314">
	  <name>Department of Palliative Medicine</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS2 8ED</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients 18 and over newly referred to PCT
2. Able to understand instructions and provide written consent within one day of referral
3. Physically and emotionally well enough to consider participating in a study and to reflect on their illness experience with a researcher
4. Not likely to be discharged with 24 hours of referral. PCT advice requested urgently
5. No strong preference expressed by the patient or patient's clinician for the visiting service of the PCT only
6. Aware of diagnosis
7. Willing to answer questions and be followed up for 4 weeks</inclusion>
      <ageRange>Not Specified</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Written consent not provided within one day of referral.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Symptoms and general pathology: Pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. The visiting service: (the usual service delivered by the Palliative Care Team.) Initial assessment by a specialist doctor/nurse with detailed advice about problems identified in patient's case notes. Follow-up by telephone and in-person consultations with patient, family and medical and nursing staff caring for patient. Liaison also with community-based health professions and palliative care outpatient follow-up if appropriate. Advice and support provided only but over and above the normal service provided to hospital patients.
2.  The telephone service: A more limited form of intervention devised as the control. No direct contact between the Palliative Care Team and the patient or family. Telephone consultation took place within one working day of referral between a senior medical PCT member and the referring doctor and also between a clinical nurse specialist and a member of the ward nursing staff involved in the patient's care. A second telephone consultation could be made if necessary but with no further follow-up or advice offered. 

Patients randomised to either the visiting service or the telephone service in order to compare: pain, symptom control and global health-related 'quality of life'; satisfaction of patients, carers and health professionals; and use of health service resources.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12232756 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="cbb3e5a7-2a52-4b29-90e0-ddd7f7b7f5a3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-09-23T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12232756"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5779-0</funderId>
      <contactId>Contact7264_5779</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7264_5779">
    <title>Prof</title>
    <forename>Geoff</forename>
    <surname>Hanks</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Palliative Medicine
University of Bristol
Bristol Oncology Centre
Horfield Road</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS2 8ED</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)117 928 3336</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">G.W.Hanks@bris.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5779-0">
    <name>NHS Cancer National Research and Development Programme (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-22T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2003-08-18T00:00:00.000Z">01982076</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>RheumAFooT (Rheumatoid Arthritis Foot Trial)</title>
      <scientificTitle/>
      <acronym>RheumAFooT</acronym>
      <studyHypothesis>The aim of this trial is to compare podiatry with no podiatry footcare in rheumatoid arthritis (RA) patients with painful and disabling foot symptoms.

The objectives are:
Primary objective: To compare foot health status (activities, impairment, participation and shoe) between active and control groups using the Leeds Foot Impact Scale.
Secondary objective 1: To compare foot function (spatial and temporal gait parameters) between the two groups using instrumented gait analysis.
Secondary objective 2: To test whether the effect of podiatry, as measured by Leeds Foot Impact Scale, is correlated with patient sex, disease duration and degree of initial foot health status.
Secondary objective 3: To determine the cost effectiveness of podiatry care for RA related foot problems.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary outcome: change in Leeds Foot Impact Scale score between baseline and 12 months.</primaryOutcome>
      <secondaryOutcome>Disease activity score, health assessment questionnaire and walking speed were also recorded.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN01982076</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G108/397</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-09-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="98dea71b-cb91-4a8c-af23-5b1287e86b78">
	  <name>Academic Unit of Musculoskeletal Disease</name>
	  <address/>
	  <city>Leeds</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>LS2 9NZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients will be suitable for inclusion if they have a definite diagnosis of RA (satisfying the 1987 American Rheumatism Association revised criteria for RA), are between 18-80 years of age and can read and write English. Patients must also have a current history of foot impairment as determined by standard history and clinical examination techniques and a Leeds Foot Impact Scale score of ≥15 points. Patients must also have stable drug management in the 3 months prior to recruitment including Disease Modifying Anti-Rheumatic Drugs, Non-Steroidal Anti-Inflammatory Drugs and oral corticosteroids.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="80.0"/>
      <gender>Both</gender>
      <targetEnrolment>34</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>34</totalTarget>
      <exclusion>Patients will be excluded if they have foot problems related to and require treatment under the appropriate medical specialty such as diabetes and peripheral vascular disease.  Patients will be excluded if they have severe complications of their RA resulting in active or high risk of developing foot ulceration.  On medical consultation, any patient with foot problems, such as ulceration and infection, likely to complicate systematic treatment with biologic and other immunosuppressant therapy (Infliximab, Etanercept, Anakinra, Cyclophosphamide, Cyclosporin, Azathioprine and any new, including trial, biologic - even if placebo) will be excluded.  Those patients who have received podiatry treatment at Leeds General Infirmary Foot Health Department in the last 3 months will also be excluded.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-09-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Active treatment arm: 12 months podiatry care
Control treatment arm: 12 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17986338 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ac555694-2988-4b34-af7e-8cfd59cab7f2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-06T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17986338"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5154-0</funderId>
      <contactId>Contact5583_5154</contactId>
      <sponsorId>Sponsor5269</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5583_5154">
    <title>Dr</title>
    <forename>James</forename>
    <surname>Woodburn</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Unit of Musculoskeletal Disease
School of Medicine
University of Leeds</address>
      <city>Leeds</city>
      <country>United Kingdom</country>
      <zip>LS2 9NZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)113 343 4938</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.woodburn@leeds.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5269">
    <organisation>Medical Research Council (UK)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W1B 1AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7670 5259</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">clinical.trial@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder5154-0">
    <name>Medical Research Council (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-14T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2002-12-20T00:00:00.000Z">10001875</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of Internet instructions on men with prostate cancer</title>
      <scientificTitle/>
      <acronym>I3MPACT</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10001875</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0c26368a-2cfe-4f82-85c6-d3df4003900a">
	  <name>Centre for Global eHealth Innovation</name>
	  <address/>
	  <city>Toronto, ON</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M5G 2C4</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Newly diagnosed prostate cancer patients</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Male</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Newly diagnosed prostate cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Prostate</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention is a face-to-face Internet training course. Class participants will get a basic introduction into how the Internet works, how to use search engines and directories, where to find interesting cancer resources including self-help groups, and how to evaluate the quality of information. The aim of the class is to guide participants to high quality information resources and online self-support groups on the web, teach critical appraisal skills, and to stimulate and motivate cancer patients to actively seek information and connect with peers via the Internet.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder1506-0</funderId>
      <contactId>Contact5100_1506</contactId>
      <sponsorId>Sponsor5012</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5100_1506">
    <title>Dr</title>
    <forename>Gunther</forename>
    <surname>Eysenbach</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre for Global eHealth Innovation
Toronto General Hospital
R Fraser Elliott Building, 4th Floor
Room # 4S435
190 Elizabeth Street</address>
      <city>Toronto, ON</city>
      <country>Canada</country>
      <zip>M5G 2C4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 416 340 4800 ext 6427</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">geysenba@uhnres.utoronto.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5012">
    <organisation>Change Foundation (Canada)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>200 Front Street West
Suite 2800</address>
      <city>Toronto, Ontario</city>
      <country>Canada</country>
      <zip>M5V 3L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder1506-0">
    <name>Change Foundation, Toronto</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2001-05-18T00:00:00.000Z">52488382</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Continuous versus intermittent antiretroviral treatment among Human Immunodeficiency Virus (HIV)-infected individuals in a gold mining community in South Africa</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52488382</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G0100484</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>Never funded, never started</reasonAbandoned>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>South Africa</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4f8fbc49-97f6-4ce8-89c9-68b37ef59319">
	  <name>Clinical Research Unit</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>WC1E 7HT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>HIV, Acquired Immunodeficiency Syndrome (AIDS)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>HIV</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Continuous versus intermittent antiretroviral treatment. September 2005: the study was never funded and never started.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Antiretrovirals</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder1324-0</funderId>
      <contactId>Contact5007_1324</contactId>
      <sponsorId>Sponsor5055</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5007_1324">
    <title>Dr</title>
    <forename>Alison</forename>
    <surname>Grant</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical Research Unit
London School of Hygiene and Tropical Medicine
Keppel Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1E 7HT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7927 2304</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">alison.grant@lshtm.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5055">
    <organisation>Medical Research Council (MRC) (UK)</organisation>
    <website>http://www.mrc.ac.uk</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1B 1AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 5422</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">clinical.trial@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder1324-0">
    <name>Medical Research Council</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2001-02-28T00:00:00.000Z">18525328</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective comparison of two schedules of radiotherapy for stage I seminoma of the testis following orchidectomy</title>
      <scientificTitle/>
      <acronym>TE18</acronym>
      <studyHypothesis>This trial was designed to compare the efficacy and the acute and long-term morbidity of standard radiotherapy with 30 Gy in 15 fractions versus 20 Gy in 10 fractions in patients with stage I seminoma testis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Relapse-free rate, with relapse defined as the development of new masses (detected clinically or radiologically), or increasing tumor-specific markers (AFP, HCG).</primaryOutcome>
      <secondaryOutcome>Impact of dose on acute morbidity and quality of life.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Local ethical committee approval was obtained from each participating centre.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18525328</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>TE18</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-01-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-01-03T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a1600698-02b2-4df4-aa7b-33986a929fe0">
	  <name>MRC Clinical Trials Unit</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>NW1  2DA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Histologically confirmed seminomatous germ cell tumour of the testis that is categorised as either 'Classical' or 'Anaplastic'  
2. Stage I disease, based on clinical and radiologic examination, and normal postorchidectomy Alpha-FetoProtein (AFP) and Human Chorionic Gonadotropin (HCG)   
3. All 'T' categories of primary tumour are eligible except those with involvement of the cut end of the spermatic cord
4. Patients with previous inguino-pelvic or scrotal surgery, have to be treated with 'dog-leg' fields
5. The interval between orchidectomy and randomisation should not exceed eight weeks. Treatment should start within two weeks thereafter
6. Consent to be randomised into the proposed study</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>1. Increased serum alphafetoprotein (AFP) (but not human chorionic gonadotropin [HCG]) preorchidectomy
2. Coexistent or previously treated malignant disease or other condition or factor preventing adherence to the study schedule and follow-up</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-01-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-01-03T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Stage I seminoma testis</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Testicular cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. One group receives 30 Gy, given in 15 daily (Monday through Friday) fractions of 2 Gy
2. The other group receives 20 Gy in 10 daily fractions of 2 Gy

Follow-up assessments will take place every three months in year one, every four months in year two, every six months in year three, and annually until year ten. Clinical examination and serum tumors markers will be required at each visit; chest x-rays are required at the six, 12-, 20-, 30-, and 36-month visits; and Computed Tomography (CT) scans of chest, abdomen, and pelvis are required at the 12-, 24-, and 36-month visits.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in https://pubmed.ncbi.nlm.nih.gov/15718317/
2005 Other publications in https://pubmed.ncbi.nlm.nih.gov/16170196</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4a50d824-e064-4adc-af23-a8e09bf51fd4" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-02-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15718317/"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="d34ea4fa-3dc7-41b6-96ac-c56edd0f26c7" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-09-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16170196"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder1036-0</funderId>
      <contactId>Contact5195_1036</contactId>
      <sponsorId>Sponsor5055</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5195_1036">
    <title>Miss</title>
    <forename>Sharon</forename>
    <surname>Naylor</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>MRC Clinical Trials Unit
222 Euston Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>NW1  2DA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5055">
    <organisation>Medical Research Council (MRC) (UK)</organisation>
    <website>http://www.mrc.ac.uk</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1B 1AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 5422</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">clinical.trial@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder1036-0">
    <name>Medical Research Council (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/501100000265</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2000-09-21T00:00:00.000Z">99228798</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Masaka Senga Trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99228798</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G0000525</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>MRC funding not obtained</reasonAbandoned>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Uganda</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="02ea8ad1-1fd9-4100-a75c-384eacea9194">
	  <name>Medical Research Council Programme on AIDS</name>
	  <address/>
	  <city>Entebbe</city>
	  <state/>
	  <country>Uganda</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Human Immunodeficiency Virus (HIV), Acquired Immunodeficiency Syndrome (AIDS)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human Immunodeficiency Virus (HIV), Acquired Immunodeficiency Syndrome (AIDS)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Not provided at time of registration. Trial not started</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder1281-0</funderId>
      <contactId>Contact5215_1281</contactId>
      <sponsorId>Sponsor5055</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5215_1281">
    <title>Dr</title>
    <forename>Anatoli </forename>
    <surname>Anatoli Kamali </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Research Council Programme on AIDS 
Uganda Virus Research Institute 
PO Box 49</address>
      <city>Entebbe</city>
      <country>Uganda</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Anatoli.Kamali@mrcuganda.org</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5055">
    <organisation>Medical Research Council (MRC) (UK)</organisation>
    <website>http://www.mrc.ac.uk</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1B 1AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 5422</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">clinical.trial@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder1281-0">
    <name>Applied for funding to UK Medical Research Council &amp; other sources of funding but unsucessfully.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2000-09-21T00:00:00.000Z">87389715</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of Human Immunodeficiency Virus (HIV) incidence of mass treatment in combination with syndromic management of sexually transmitted infections, with or without acyclovir</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87389715</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>G0000527</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>Lack of funding</reasonAbandoned>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Uganda</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4420484d-74f8-4704-a7b7-35f04de120c4">
	  <name>Medical Research Council Programme on AIDS</name>
	  <address/>
	  <city>Entebbe</city>
	  <state/>
	  <country>Uganda</country>
	  <zip/>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>HIV, Acquired Immunodeficiency Syndrome (AIDS)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>HIV, Acquired Immunodeficiency Syndrome (AIDS)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Not provided at time of registration</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>acyclovir</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder1300-0</funderId>
      <contactId>Contact5027_1300</contactId>
      <sponsorId>Sponsor5055</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact5027_1300">
    <title>Dr</title>
    <forename>Anatoli</forename>
    <surname>Kamali</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Research Council Programme on AIDS
Uganda Virus Research Institute
PO Box 49</address>
      <city>Entebbe</city>
      <country>Uganda</country>
      <zip/>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+256 (0) 41 320042/320272</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mrc@starcom.co.ug</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5055">
    <organisation>Medical Research Council (MRC) (UK)</organisation>
    <website>http://www.mrc.ac.uk</website>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>20 Park Crescent</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>W1B 1AL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7636 5422</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">clinical.trial@headoffice.mrc.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder1300-0">
    <name>Applied for funding to UK Medical Research Council &amp; other sources of funding but unsucessfully.</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>